Use these links to rapidly review the
document
TABLE OF
CONTENTS
Table of
Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy
Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment
No. )
|
|
|
Filed by
the Registrant ý |
Filed by a Party other than the Registrant
o |
Check the appropriate box: |
o |
|
Preliminary Proxy Statement |
o |
|
Confidential, for Use of the Commission Only (as
permitted by Rule 14a-6(e)(2)) |
ý |
|
Definitive Proxy Statement |
o |
|
Definitive Additional Materials |
o |
|
Soliciting Material under
§240.14a-12
|
|
|
|
|
|
COMMUNITY HEALTHCARE TRUST
INCORPORATED |
(Name of Registrant as Specified In Its
Charter) |
Not Applicable |
(Name of Person(s) Filing Proxy Statement, if other
than the Registrant) |
Payment of Filing Fee (Check the appropriate box): |
ý |
|
No fee required. |
o |
|
Fee computed on table below per Exchange Act Rules
14a-6(i)(1) and 0-11. |
|
|
(1) |
|
Title of each class of securities to which
transaction applies:
|
|
|
(2) |
|
Aggregate number of securities to which transaction
applies:
|
|
|
(3) |
|
Per unit price or other underlying value of
transaction computed pursuant to Exchange Act Rule 0-11 (set forth
the amount on which the filing fee is calculated and state how it
was determined):
|
|
|
(4) |
|
Proposed maximum aggregate value of transaction:
|
|
|
(5) |
|
Total fee paid:
|
o |
|
Fee paid previously with preliminary
materials. |
o |
|
Check box if any part of the fee is offset as
provided by Exchange Act Rule 0-11(a)(2) and identify the
filing for which the offsetting fee was paid previously. Identify
the previous filing by registration statement number, or the Form
or Schedule and the date of its filing. |
|
|
(1) |
|
Amount Previously Paid:
|
|
|
(2) |
|
Form, Schedule or Registration Statement No.:
|
|
|
(3) |
|
Filing Party:
|
|
|
(4) |
|
Date Filed:
|
Table of
Contents

March 20, 2020
Dear
Stockholder:
On behalf of
the Board of Directors, we cordially invite you to attend the 2020
annual meeting of stockholders of Community Healthcare Trust
Incorporated, a Maryland corporation (the "Company"). The annual
meeting will be held beginning at 8:00 a.m., Central time, on
Thursday, May 7, 2020 at the principal offices of the Company,
located at 3326 Aspen Grove Drive, Suite 150, Franklin,
Tennessee 37067. The formal notice of the annual meeting
appears on the next page. At the annual meeting, you will be asked
to:
- 1.
- Elect five directors,
each to serve a one-year term expiring in 2021;
- 2.
- Vote to approve, on a
non-binding advisory basis, a resolution approving the Company's
compensation of its named executive officers;
- 3.
- Vote to approve, on a
non-binding advisory basis, the frequency of a non-binding advisory
vote on executive compensation;
- 4.
- Ratify the
appointment of BDO USA, LLP as our independent registered
public accountants for 2020; and
- 5.
- Transact such other
business as may properly come before the annual meeting or any
adjournment or postponement thereof.
The
accompanying proxy statement provides detailed information
concerning the matters to be acted upon at the annual meeting. We
urge you to review this proxy statement and each of the proposals
carefully. Your vote is very important. It is important that your
views be represented at the annual meeting regardless of the number
of shares of common stock you own or whether you are able to attend
the annual meeting in person.
On
March 20, 2020, we posted on the investor's relations page of
our Internet website, http://investors.chct.reit, a copy
of our 2020 proxy statement, proxy card and our annual report to
stockholders. Also, on or around March 20, 2020, we mailed a
notice (the "Notice") containing instructions on how to access our
proxy materials and vote online to our institutional stockholders
who own our stock directly in their name and in the name of other
stockholders.
You may vote
your shares on the Internet. If you request a paper copy of the
proxy card or voting instruction form, we will mail you the paper
copy and you may sign, date and mail the accompanying proxy card or
voting instruction form in the envelope provided with your proxy
card. Instructions regarding the two methods of voting by proxy are
contained on the Notice and on the proxy card. As always, if you
are the record holder of our stock, you may vote in person at the
annual meeting. The accompanying proxy statement explains how to
obtain driving directions to the meeting.
Table of
Contents
On behalf of
our Board of Directors, I would like to express our appreciation
for your continued interest in Community Healthcare Trust
Incorporated.
|
|
|
|
|
Sincerely, |
|
|
Timothy G. Wallace Chairman of the
Board, President, and
Chief Executive Officer |
Important Notice Regarding the Availability of Proxy
Materials for
the Stockholder Meeting to be held on May 7,
2020:
Community Healthcare Trust Incorporated's 2020 proxy statement,
proxy card and annual report to
stockholders are available at http://investors.chct.reit.
Table of
Contents
Community Healthcare Trust Incorporated
3326 Aspen Grove Drive, Suite 150
Franklin, Tennessee 37067
NOTICE OF
ANNUAL MEETING OF STOCKHOLDERS
|
|
|
TIME |
|
8:00 a.m., Central Time, on Thursday, May 7,
2020 |
PLACE |
|
Community Healthcare Trust Incorporated
3326 Aspen Grove Drive, Suite 150
Franklin, Tennessee 37067 |
ITEMS OF BUSINESS |
|
1. To elect five directors, each to serve a one-year
term expiring in 2021; |
|
|
2. To vote to approve, on a non-binding advisory
basis, a resolution approving the Company's compensation of its
named executive officers; |
|
|
3. To vote to approve, on a non-binding advisory
basis, the frequency of a non-binding advisory vote on executive
compensation; |
|
|
4. To ratify the appointment of BDO USA, LLP as
our independent registered public accountants for 2020;
and |
|
|
5. To transact such other business as may properly
come before the annual meeting or any adjournment or postponement
thereof. |
RECORD DATE |
|
You can vote if you are a stockholder of record as
of the close of business on March 6, 2020. |
ANNUAL REPORT |
|
All of these documents are accessible on our
Internet website, http://investors.chct.reit. You
may request a paper copy of the proxy statement, the proxy card,
and our annual report to stockholders, which is not part of the
proxy solicitation material. |
PROXY VOTING |
|
It is important that your shares be represented and
voted at the annual meeting. You may vote your shares on the
Internet or, if you request and receive written proxy materials,
you may vote by signing, dating and mailing the accompanying proxy
card or voting instruction form in the envelope provided.
Instructions regarding the two methods of voting are contained on
the proxy card. The Notice has instructions regarding voting on the
Internet. Any proxy may be revoked at any time prior to its
exercise at the annual meeting. |
|
|
|
|
|
By Order of the Board
of Directors, |
|
|
 |
|
|
W. Page Barnes Secretary of
Community Healthcare Trust Incorporated
Franklin, Tennessee
March 20, 2020
|
Table of
Contents
COMMUNITY HEALTHCARE TRUST INCORPORATED
PROXY STATEMENT
INDEX
|
|
|
Questions and Answers Regarding the 2020 Annual
Meeting of Stockholders
|
|
1 |
Proposal 1—Election of Directors
|
|
4 |
Corporate Governance
|
|
8 |
Compensation Discussion and Analysis
|
|
16 |
Compensation Committee Report
|
|
27 |
Compensation Committee Interlocks and Insider
Participation
|
|
27 |
Executive Officers
|
|
28 |
Compensation Tables
|
|
31 |
Equity Compensation Plan Information
|
|
35 |
Proposal 2—Non-Binding Advisory Vote on Executive
Compensation
|
|
36 |
Proposal 3—Non-Binding Advisory Vote on the
Frequency of the Vote on Executive Compensation
|
|
37 |
Proposal 4—Ratification of the Appointment of BDO
USA, LLP as Our Independent Registered Public Accountants for
2020
|
|
38 |
Report of the Audit Committee
|
|
40 |
Beneficial Ownership of Shares of Common
Stock
|
|
42 |
Certain Relationships and Related Party
Transactions
|
|
44 |
Stockholder Proposals for the 2021 Annual
Meeting
|
|
45 |
Other Matters
|
|
45 |
Appendix A—Reconciliation of Non-GAAP Financial
Measures
|
|
46 |
Table of
Contents
COMMUNITY HEALTHCARE TRUST INCORPORATED
PROXY STATEMENT
ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON THURSDAY, MAY 7, 2020
We are
furnishing this proxy statement to the stockholders of Community
Healthcare Trust Incorporated in connection with the solicitation
of proxies by its Board of Directors for use at the annual meeting
of stockholders of Community Healthcare Trust Incorporated to be
held at 8:00 a.m., Central time, on Thursday, May 7,
2020, at 3326 Aspen Grove Drive, Suite 150, Franklin,
Tennessee 37067, as well as in connection with any
adjournments or postponements of the meeting. This solicitation is
made by Community Healthcare Trust Incorporated on behalf of our
Board of Directors (also referred to as the "Board" in this proxy
statement). "We," "our," "us" and the "Company" refer to Community
Healthcare Trust Incorporated, a Maryland corporation.
We have elected
to provide access to our proxy materials and annual report over the
Internet through a "notice and access" model. Accordingly, we are
sending a Notice of Internet Availability of Proxy Materials (the
"Notice") to our stockholders of record as of March 6, 2020.
All stockholders will have the ability to access the proxy
materials on the website referred to in the Notice or to request a
printed set of the proxy materials. Instructions on how to request
a printed copy by mail or electronically may be found on the Notice
and on the website referred to in the Notice, including an option
to request paper copies on an ongoing basis. On March 20,
2020, we intend to make this proxy statement available on the
Internet and, on or around March 20, 2020, we intend to mail
the Notice to all stockholders entitled to vote at the annual
meeting. We intend to mail this Proxy Statement, together with a
proxy card, to those stockholders entitled to vote at the annual
meeting who have properly requested paper copies of such materials,
within three business days of such receipt.
This proxy
statement, proxy card and our annual report to stockholders are
available at http://investors.chct.reit. This
website address contains the following documents: the Notice, the
proxy statement and proxy card sample, and the annual report to
stockholders. You are encouraged to access and review all of the
important information contained in the proxy materials before
voting.
QUESTIONS AND ANSWERS REGARDING THE 2020 ANNUAL
MEETING OF
STOCKHOLDERS
Who is soliciting proxies from the stockholders?
Our Board of
Directors is soliciting your proxy. The proxy provides you with the
opportunity to vote on the proposals presented at the annual
meeting, whether or not you attend the annual meeting.
What will be voted on at the annual meeting?
Our
stockholders will vote on four proposals at the annual
meeting:
- 1.
- The election of five
directors, who are each to serve a one-year term expiring in
2021;
- 2.
- The approval of, on a
non-binding advisory basis, a resolution approving the Company's
compensation of its named executive officers;
- 3.
- The approval of, on a
non-binding advisory basis, the frequency of a non-binding advisory
vote on executive compensation; and
- 4.
- The ratification of
the appointment of BDO USA, LLP as our independent registered
public accountants for 2020.
1
Table of
Contents
Your proxy will
also give the proxy holders discretionary authority to vote the
shares represented by the proxy on any matter, other than the above
proposals, that is properly presented for action at the annual
meeting.
How will we solicit proxies, and who bears the cost of proxy
solicitation?
Our directors,
officers and employees may solicit proxies by telephone, mail,
facsimile, via the Internet or by overnight delivery service. These
individuals do not receive separate compensation for these
services. Finally, in accordance with the rules and regulations of
the U.S. Securities and Exchange Commission (the "SEC"), we will
reimburse brokerage firms and other persons representing beneficial
owners of our common stock for their reasonable expenses in
forwarding solicitation materials to such beneficial
owners.
Who can vote at the annual meeting?
Our Board of
Directors has fixed the close of business on Friday, March 6,
2020, as the record date for our annual meeting. Only stockholders
of record on that date are entitled to receive notice of and vote
at the annual meeting. As of March 6, 2020, our only
outstanding class of securities was common stock, $0.01 par value
per share. On that date, we had 450,000,000 shares of common stock
authorized, of which 21,906,352 shares were outstanding.
You (if you,
rather than your broker, are the record holder of our stock) can
vote either in person at the annual meeting or by proxy, whether or
not you attend the annual meeting. If you would like to attend the
annual meeting in person and need directions, please contact W.
Page Barnes by e-mail at investorrelations@chct.reit or by
telephone at 615-771-3052. You may vote your shares on the Internet
or, to the extent you request written proxy materials, by signing,
dating and mailing the accompanying proxy card in the envelope
provided. Instructions regarding the two methods of voting by proxy
are contained on the proxy card.
How many votes must be present to hold the annual
meeting?
A quorum must
be present to hold our annual meeting. The presence, in person or
by proxy, of a majority of the votes entitled to be cast at the
annual meeting constitutes a quorum. Your shares, once represented
for any purpose at the annual meeting, are deemed present for
purposes of determining a quorum for the remainder of the meeting
and for any adjournment, unless a new record date is set for the
adjourned meeting. This is true even if you abstain from voting
with respect to any matter brought before the annual meeting. As of
March 6, 2020, we had 21,906,352 shares of common stock
outstanding; thus, we anticipate that the quorum for our annual
meeting will be 10,953,177 shares.
How many votes does a stockholder have per share?
Our
stockholders are entitled to one vote for each share
held.
What is the required vote on each proposal?
Directors are
elected by a plurality vote; the candidates up for election who
receive the highest number of votes cast, up to the number of
directors to be elected, are elected. Stockholders do not have the
right to cumulate their votes.
The affirmative
vote of a majority of the shares represented at the meeting and
entitled to vote is required to approve, on an advisory basis, the
say on pay vote. As an advisory vote, this proposal is not binding
upon us. However, the Compensation Committee of our Board of
Directors, which is responsible for designing and administering our
executive compensation program, values the opinions
2
Table of
Contents
expressed by our
stockholders and will consider the outcome of the vote when making
future compensation decisions.
The affirmative
vote of a majority of the shares represented at the meeting and
entitled to vote is required to approve, on an advisory basis, the
frequency of future stockholder say on pay votes. As an advisory
vote, this proposal is not binding upon us. The Compensation
Committee of our Board of Directors will consider the outcome of
the vote when determining the frequency of holding future
stockholder say on pay votes.
The proposal to
ratify our appointment of BDO USA, LLP, or BDO, as our
independent registered public accountants for 2020, is approved by
our stockholders if the votes cast favoring the ratification exceed
the votes cast opposing the ratification.
How will the proxy be voted, and how are votes
counted?
If you vote by
proxy (either voting on the Internet or by properly completing and
returning a paper proxy card that you receive upon requesting
written proxy materials), the shares represented by your proxy will
be voted at the annual meeting as you instruct, including any
adjournments or postponements of the meeting. If you return a
signed proxy card but no voting instructions are given, the proxy
holders will exercise their discretionary authority to vote the
shares represented by the proxy at the annual meeting and any
adjournments or postponements as follows:
- 1.
- "FOR" the election of nominees Alan
Gardner, Claire Gulmi, Robert Hensley, Lawrence Van Horn, and
Timothy Wallace.
- 2.
- "FOR" the resolution approving the
compensation of the Company's named executive officers.
- 3.
- "ANNUAL" vote on executive
compensation.
- 4.
- "FOR" the ratification of the
appointment of BDO USA, LLP as our independent registered
public accountants for 2020.
If you hold
your shares in broker's name (sometimes call "street name" or
"nominee name"), you must provide voting instructions to your
broker. If you do not provide instructions to your broker, your
shares will not be voted in any matter on which your broker does
not have discretionary authority to vote, which generally includes
non-routine matters. A vote that is not cast for this reason is
called a "broker non-vote." Broker non-votes will be treated as
shares present for the purpose of determining whether a quorum is
present at the annual meeting, but they will not be considered
present for purposes of calculating the vote on a particular
matter, nor will they be counted as a vote FOR or AGAINST a matter
or as an abstention on the matter. Under the rules of the New York
Stock Exchange ("NYSE"), which is the stock exchange on which our
common stock is listed, the ratification of our appointment of our
independent registered public accountants is considered a routine
matter for broker voting purposes, but the election of directors,
the advisory (non-binding) vote on the compensation of our named
executive officers, and the advisory (non-binding) vote on the
frequency of future stockholder votes on the compensation of our
named executive officers are not considered routine. It is
important that you instruct your broker as to how you wish to have
your shares voted, even if you wish to vote as recommended by the
Board.
Can a proxy be revoked?
Yes. You can
revoke your proxy at any time before it is voted. You revoke your
proxy (1) by giving written notice to our Corporate Secretary
before the annual meeting, (2) by granting a subsequent proxy
on the Internet, or (3) by delivering a signed proxy card
dated later than your previous proxy. If you, rather than your
broker, are the record holder of your stock, a proxy can also be
revoked by appearing in person and voting at the annual meeting.
Written notice of the revocation of a proxy should be delivered to
the following address: W. Page Barnes, Community Healthcare Trust
Incorporated, 3326 Aspen Grove Drive, Suite 150, Franklin,
Tennessee 37067.
3
Table of
Contents
PROPOSAL 1
ELECTION OF DIRECTORS
The persons
listed below have been nominated by our Board of Directors to serve
as directors for a one-year term expiring at the annual meeting of
stockholders occurring in 2021: Alan Gardner, Claire Gulmi, Robert
Hensley, Lawrence Van Horn and Timothy Wallace. Each nominee has
consented to serve on our Board of Directors. If any nominee were
to become unavailable to serve as a director, our Board of
Directors may designate a substitute nominee. In that case, the
persons named as proxies on the accompanying proxy card will vote
for the substitute nominee designated by our Board of Directors.
The following lists each director nominated for election to serve
as a director for a one-year term expiring at the annual meeting of
stockholders occurring in 2021, which includes a brief discussion
of the experience, qualifications and skills that led us to
conclude that such individual should be a member of our
Board.
Qualifications of Directors
We believe that
our Board of Directors consists of a diverse collection of
individuals who possess the integrity, education, work ethic and
ability to work with others necessary to oversee our business
effectively and to represent the interests of all stockholders,
including the qualities listed below. We have attempted below to
highlight certain notable experience, qualifications and skills for
each director nominee, rather than provide an exhaustive catalog of
each and every qualification and skill that a director possesses.
Each of the nominees set forth below is currently serving as a
director of the Company.
|
|
|
|
|
Name
|
|
Age |
|
Background, Qualifications and Skills |
Alan
Gardner |
|
66 |
|
Mr. Gardner retired from Wells Fargo in October 2015.
Prior to his retirement, he was a senior relationship manager in
healthcare corporate banking. He primarily covered national
healthcare companies with market capitalization exceeding
$5 billion, generally in the pharmaceutical, medical device
and healthcare services sectors. Mr. Gardner has over
26 years of corporate and investment banking experience, with
20 years covering healthcare companies. Prior to joining Wells
Fargo (Wachovia) in March 2004, Mr. Gardner was head of
healthcare for FleetBoston Financial from 2003 to 2004 and was a
managing director for Banc of America Securities from 1996 to 2003.
During his career, Mr. Gardner has led a number of significant
financing transactions for leading public healthcare companies.
Mr. Gardner previously served as board member and president of
Omni Montessori School in Charlotte, North Carolina, as Charlotte
Chapter chair for the Impact Angel Network ("IAN"). IAN is managed
by RENEW, LLC, an investment advisory and management
consulting firm based in Addis Ababa, Ethiopia and Washington D.C.
and on the board of directors at Christ Lutheran Church in
Charlotte, North Carolina. Mr. Gardner earned a B.S. and M.S.
from Virginia Polytechnic Institute and State University and an
M.B.A. in finance and accounting from the University of Rochester.
Mr. Gardner is our lead independent director, and
Mr. Gardner's commercial banking, capital markets and
healthcare industry experience makes him a valuable resource to our
Board of Directors. |
4
Table of
Contents
|
|
|
|
|
Name
|
|
Age |
|
Background, Qualifications and Skills |
Claire
Gulmi |
|
66 |
|
Ms. Gulmi served as Executive Vice President and Chief
Financial Officer of Envision Healthcare, a $7 billion public
company, the largest owner/operator of ambulatory surgery centers
in the United States and a leading provider of hospital based
physician services, until her retirement in October 2017.
Ms. Gulmi continued to serve as an advisor to Envision until
September 2018. Prior to Envision's merger with AmSurg Corp in
2016, Ms. Gulmi served as Executive Vice President and Chief
Financial Officer of AmSurg starting in 1994. She was a member of
the Board of Directors of AmSurg from 2004 until the merger in
2016. From 2015 to 2017, Ms. Gulmi served on the Board of
Directors and as the audit committee chair of Air Methods Corp, a
$1.5 billion public company and the largest provider of air
medical emergency transport services in the U.S. From 2001 to 2015
she served on the advisory board of the Bank of Nashville.
Ms. Gulmi has a BBA in Accounting and Finance from Belmont
University. Ms. Gulmi is the past board chair of the YWCA of
Nashville, serves on the boards of the Frist Center for the Visual
Arts and Nashville Public Radio. She has served as board chair for
the Bethlehem Centers of Nashville and has served on the boards of
the Girl Scouts, the American Heart Association and All About
Women. Ms. Gulmi has been named by the Nashville Business
Journal as one of its Healthcare 100, was one of the 2007 winners
of the Nashville Business Journal's Women of Influence and in 2011
received the Nashville Business Journal's CFO Lifetime Achievement
Award. Ms. Gulmi's over 30 years of experience in
corporate finance, accounting and healthcare makes her a valuable
resource to our Board of Directors. |
Robert Hensley |
|
62 |
|
Mr. Hensley has more than 35 years of
experience serving public and privately-held companies across a
range of industries, including healthcare, insurance, real estate
and private equity capital funds. Mr. Hensley is also the
founder of a private publishing company and the principal owner of
two real estate and rental property development companies.
Mr. Hensley was an audit partner with Ernst & Young
from 2002 to 2003. Previously, he was with Arthur Andersen, where
he served as an audit partner from 1990 to 2002 and was the
managing partner of their Nashville office from 1997 to 2002. His
significant experience includes mergers and acquisitions,
identification of enterprise and healthcare industry risks,
corporate governance and forensic investigations and disputes.
Since 2006, Mr. Hensley has served as a senior advisor to the
healthcare and transaction advisory services groups of Alvarez and
Marsal, LLC ("A&M"). Mr. Hensley serves on the board
of directors for Diversicare Healthcare Services, Inc.
Mr. Hensley previously served as a director of Capella
Healthcare from 2008 to 2015, Greenway Medical Technologies from
2011 to 2013, HealthSpring, Inc. from 2006 to 2012 and Comsys
IT Partners, Inc. and Spheris, Inc. from 2006 to 2010.
Mr. Hensley earned a B.S. in accounting and a Master's of
Accountancy from the University of Tennessee and is a Certified
Public Accountant. Mr. Hensley's financial accounting,
healthcare industry and transactional experience makes him a
valuable resource to our Board of Directors. |
5
Table of
Contents
|
|
|
|
|
Name
|
|
Age |
|
Background, Qualifications and Skills |
Lawrence Van
Horn |
|
52 |
|
Professor Van Horn has been an associate professor of Economics
and Management and the Executive Director of Health Affairs at the
Vanderbilt University Owen Graduate School of Management ("Owen")
since 2006. Professor Van Horn is a leading expert and researcher
on healthcare management and economics. His current research
interests include nonprofit conduct, governance and objectives in
healthcare markets and the measurement of healthcare outcomes and
productivity. His research on healthcare organizations, managerial
incentives in nonprofit hospitals and the conduct of managed care
firms has appeared in leading publications. Professor Van Horn
consults for national consulting firms, providers, managed care
organizations, and pharmaceutical firms. Professor Van Horn also
holds faculty appointments in the Vanderbilt University School of
Medicine and Law School. Prior to his tenure at Owen, from 1996 to
2006, Professor Van Horn served as an associate professor of
economics and management at the William E. Simon Graduate School of
Business at the University of Rochester where he was responsible
for their graduate programs in health administration. Professor Van
Horn began serving on the board of directors of Quorum Health
Corporation in January 2016. Professor Van Horn holds a Ph.D. from
the University of Pennsylvania's Wharton School and a Master's in
Business Administration, a Master's in Public Health and a B.A.
from the University of Rochester. Professor Van Horn's extensive
knowledge and research into healthcare industry economics and
governance as well as his unique experience with healthcare
decision makers and business executives nationwide regarding
healthcare policy make him a valuable resource to our Board of
Directors. |
Timothy Wallace |
|
61 |
|
Mr. Wallace has served as our Chairman, Chief
Executive Officer and President since the formation of our Company
in March 2014. Prior to founding our Company, from 2003 to 2014,
Mr. Wallace was co-founder, President and majority owner of
Athena Funding Partners, LLC and related entities which were
established in 2002 to provide financing solutions to the higher
education industry for on-campus student housing facilities mostly
in rural areas. From 1993 to 2002, Mr. Wallace was a
co-founder and Executive Vice President of Healthcare Realty Trust
(NYSE: HR) ("HR"). Between HR's initial public offering in 1993 and
his departure from HR in 2002, Mr. Wallace was integral in
helping to grow HR from $2,000 to over $2 billion in asset
value. Mr. Wallace remained as a paid consultant to HR and was
subject to a non-compete until 2008. Mr. Wallace was a senior
manager at Ernst & Young from 1988 to 1993.
Mr. Wallace began his career in 1980 with Arthur
Andersen & Co. Mr. Wallace holds a Bachelor of
Science in Business Administration and Masters in Business
Administration, both from Western Kentucky University.
Mr. Wallace was selected to serve as Chairman because of his
past public company experience, his experience in real estate,
including acquiring healthcare real estate, and his role as Chief
Executive Officer and President of our Company. |
Each of the
persons listed above has been nominated by our Board of Directors
to serve as directors for a one-year term expiring at the annual
meeting of stockholders occurring in 2021. Each
6
Table of
Contents
nominee has consented
to serve on our Board of Directors. If any nominee were to become
unavailable to serve as a director, our Board of Directors may
designate a substitute nominee. In that case, the persons named as
proxies on the accompanying proxy card will vote for the substitute
nominee designated by our Board of Directors.
Required Vote
Directors are
elected by a plurality vote; the nominees who receive the highest
number of votes cast, up to the number of directors to be elected
in that class, are elected.
Our Board of Directors unanimously recommends a
vote "FOR" the election of each of the five
nominees for director to the Board of Directors.
7
Table of
Contents
CORPORATE GOVERNANCE
Board Leadership Structure
Our Board of
Directors currently consists of the following five directors: Alan
Gardner, Claire Gulmi, Robert Hensley, Lawrence Van Horn and
Timothy Wallace, each for a one-year term. Our Board has
affirmatively determined that each of Alan Gardner, Claire Gulmi,
Robert Hensley, and Lawrence Van Horn is an "independent director"
as defined under the listing rules of the NYSE, Rule 10A-3
under the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), and the Company's Corporate Governance
Guidelines.
The Board
considered the relationships between our directors and the Company
when determining each director's status as an "independent
director" under the listing rules of the NYSE, Rule 10A-3 of
the Exchange Act and the Company's Corporate Governance Guidelines,
including the relationships listed below under "Certain
Relationships and Related Party Transactions" The Board determined
that these relationships did not affect any director's status as an
"independent director." Furthermore, we are not aware of any family
relationships between any director, executive officer or person
nominated to become a director or executive officer.
Timothy
Wallace, our President and Chief Executive Officer, serves as
Chairman of the Board of the Company, while Alan Gardner serves as
"Lead Independent Director" of our Board. The members of the Board
who meet the definition of "independent director" under the listing
rules of the NYSE select our lead independent director.
Mr. Wallace
serves as our Chairman because we believe this board structure
results in a single voice speaking for the Company and presents a
unified and clear chain of command to execute our strategic
initiatives and business plans. Also, the Chairman of the Board is
expected to manage the Board in performing its duties and lead
Board discussion. As our President and Chief Executive Officer,
Mr. Wallace is ideally positioned to provide insight on the
current status of our overall operations, our future plans and
prospects and the risks that we face. Thus, the individual with the
most knowledge about us and our operations is responsible for
leading the Board's discussions. The Board retains the authority to
separate the positions of chairman and chief executive officer if
it finds that the Board's responsibilities can be better fulfilled
with a different structure.
Mr. Gardner
serves as our Lead Independent Director and provides an independent
counterbalance to the Chairman, ensuring that all of our directors'
concerns are addressed and otherwise facilitating robust
discussions among the entire Board (which, as noted above, is
comprised almost entirely of "independent directors"). In terms of
Board leadership, we view the lead independent director as
essentially a co-equal with the Chairman of the Board.
Mr. Gardner has been a director since 2015 and was the second
director to join the Board following Mr. Wallace, which we
believe adds weight to his independent voice on the Board. Also, at
each meeting of our Board, Mr. Gardner leads the Board in an
executive session (that is, a meeting of only those directors who
are "independent directors" under the listing rules of the NYSE) to
discuss matters outside the presence of the Chairman and
management. Our lead independent director is selected on an annual
basis by a majority of the independent directors then serving on
our Board of Directors.
Our Lead
Independent Director Charter sets forth a complete description of
the lead independent director's responsibilities. In general, the
lead independent director is responsible for:
- •
- serving as liaison
between the Chairman and our other independent directors;
- •
- calling and presiding
at executive sessions of the independent directors;
- •
- serving as the focal
point of communication to the Board of Directors regarding
management plans and initiatives;
8
Table of
Contents
- •
- ensuring that the
management adheres to the Board of Directors' oversight role over
management operations;
- •
- providing the medium
for informal dialogue with and between independent directors,
allowing for free and open communication within that group;
and
- •
- serving as the
communication conduit for third parties who wish to communicate
with our Board of Directors.
In addition to
these specific duties, we expect the lead independent director to
familiarize himself with the Company and the real estate investment
trust and healthcare industries in general. He also is expected to
keep abreast of developments in the principles of sound corporate
governance.
The Board's Role in Risk Oversight
One of the key
functions of our Board of Directors is to provide oversight of our
risk management process. Our Board of Directors administers this
oversight function directly, with support from its three standing
committees—the Audit Committee, the Compensation Committee, and the
Corporate Governance Committee—each of which addresses risks
specific to their respective areas of oversight. In particular, our
Audit Committee has the responsibility to consider and discuss our
major financial risk exposures and the steps our management has
taken to monitor and control these exposures, including guidelines
and policies to govern the process by which risk assessment and
management is undertaken. The Audit Committee also monitors
compliance with legal and regulatory requirements and has oversight
of the performance of our internal audit function. Our Compensation
Committee assesses and monitors whether any of our compensation
policies and programs has the potential to encourage excessive
risk-taking. Our Corporate Governance Committee monitors the
effectiveness of our corporate governance guidelines, including
whether they are successful in preventing illegal or improper
liability-creating conduct.
Each committee
meets regularly with management to assist it in identifying all of
the risks within such committee's areas of responsibility and in
monitoring and, where necessary, taking appropriate action to
mitigate the applicable risks. At each Board meeting, the committee
chairman of each committee that met prior to such Board meeting
provides a report to the full Board on issues related to such
committee's risk oversight duties, as applicable. To the extent
that any risks reported to the full Board need to be discussed
outside the presence of management, the Board meets in executive
session to discuss these issues.
We believe the
Board's approach to fulfilling its risk oversight responsibilities
complements its leadership structure. In his capacity as Chairman
of the Board, Mr. Wallace reviews whether Board committees are
addressing their risk oversight duties in a comprehensive and
timely manner. Since he is also our Chief Executive Officer,
Mr. Wallace is able to assist these committees in fulfilling
their duties by (1) requiring that our management team provide
these committees with all requested reports and other information
as well as with access to our employees and (2) implementing
recommendations of the various Board committees to mitigate risk.
At the same time, Mr. Gardner, as our lead independent
director, is able to lead an independent review of the risk
assessments developed by management and reported to the
committees.
Our Board held
five meetings during 2019. In 2019, our directors attended all of
our Board meetings and at least 75% of the meetings of the
committees on which they served. The members who are "independent
directors" met in executive session four times during
2019.
We do not have
a policy requiring director attendance at our annual stockholder
meeting. Mr. Wallace and Ms. Gulmi were the only
directors of the Company to attend our 2019 annual stockholder
meeting.
9
Table of
Contents
Committees of the Board of Directors
Our Board of
Directors has three standing committees: an Audit Committee, a
Compensation Committee and a Corporate Governance Committee. The
principal functions of each committee are described below. We
currently comply, and we intend to continue to comply, with the
listing requirements and other rules and regulations of the NYSE
and each of these committees are comprised exclusively of
independent directors. Additionally, our Board of Directors may
from time to time establish certain other committees to facilitate
the management of our Company.
Audit Committee
Our Audit
Committee consists of Mr. Gardner, Ms. Gulmi, and
Mr. Hensley, all of whom are independent directors, with
Mr. Hensley serving as the chairman. Ms. Gulmi and
Mr. Hensley each qualify as an "audit committee financial
expert" as that term is defined by the applicable SEC regulations
and NYSE corporate governance listing standards. Our Board of
Directors has determined that each of the Audit Committee members
is "financially literate" as that term is defined by the NYSE
corporate governance listing standards. We have adopted an Audit
Committee Charter, which details the principal functions of the
Audit Committee, including oversight related to:
- •
- our accounting and
financial reporting processes;
- •
- the integrity of our
consolidated financial statements and financial reporting
process;
- •
- our system of
disclosure controls and procedures and internal control over
financial reporting;
- •
- our compliance with
financial, legal and regulatory requirements;
- •
- the evaluation of the
qualifications, independence and performance of our independent
registered public accounting firm;
- •
- reviewing the
adequacy of our Audit Committee Charter on an annual basis;
- •
- the performance of
our internal audit function; and
- •
- our overall risk
profile.
The Audit
Committee is also responsible for engaging an independent
registered public accounting firm, reviewing with the independent
registered public accounting firm the plans and results of the
audit engagement, approving professional services provided by the
independent registered accounting firm, including all audit and
non-audit services, reviewing the independence of the independent
registered public accounting firm, considering the range of audit
and non-audit fees and reviewing the adequacy of our internal
accounting controls.
The Audit
Committee met six times in 2019. A copy of the charter of our Audit
Committee is available on the investor relations webpage of our
website, http://investors.chct.reit.
Compensation Committee
Our
Compensation Committee consists of Mr. Gardner,
Ms. Gulmi, and Mr. Van Horn, all of whom are "independent
directors" as defined in NYSE Rule 303A.02, with
Ms. Gulmi serving as chairperson. Further, each member of the
Compensation Committee is a "non-employee director" as defined in
Rule 16b-3 promulgated under the Exchange Act. We have adopted
a Compensation Committee Charter, which details the principal
functions of the Compensation Committee, including:
- •
- reviewing and
recommending to our Board of Directors on an annual basis the
corporate goals and objectives relevant to our chief executive
officer's compensation, evaluating our chief executive officer's
performance in light of such goals and objectives and determining
and approving the remuneration of our chief executive officer based
on such evaluation;
10
Table of
Contents
- •
- reviewing and
recommending to our Board of Directors the compensation, if any, of
all of our other executive officers;
- •
- evaluating our
executive compensation policies and plans;
- •
- assisting management
in complying with our proxy statement and annual report disclosure
requirements;
- •
- administering our
incentive plans;
- •
- reviewing and
recommending to our Board of Directors policies with respect to
incentive compensation and equity compensation arrangements;
- •
- reviewing the
competitiveness of our executive compensation programs and
evaluating the effectiveness of our compensation policy and
strategy in achieving expected benefits to us;
- •
- evaluating and
overseeing risks associated with compensation policies and
practices;
- •
- reviewing and
recommending to our Board of Directors the terms of any employment
agreements, severance arrangements change in control protections
and any other compensatory arrangements for our executive
officers;
- •
- reviewing the
adequacy of its Compensation Committee Charter on an annual
basis;
- •
- producing a report on
executive compensation to be included in our annual proxy statement
as required; and
- •
- reviewing, evaluating
and recommending changes, if appropriate, to the remuneration for
directors.
The
Compensation Committee met four times in 2019. A copy of the
charter of our Compensation Committee is available on the investor
relations webpage of our website, http://investors.chct.reit.
Corporate Governance Committee
Our Corporate
Governance Committee consists of Messrs. Van Horn, Hensley and
Gardner, all of whom are "independent directors" as defined in NYSE
Rule 303A.02, with Mr. Van Horn serving as chairman. We
have adopted a Corporate Governance Committee charter, which
details the principal functions of the Corporate Governance
Committee, including:
- •
- identifying,
evaluating and recommending to the full Board of Directors
qualified candidates for election as directors and recommending
nominees for election as directors at the annual meeting of
stockholders;
- •
- developing and
recommending to the Board of Directors corporate governance
guidelines and implementing and monitoring such guidelines;
- •
- reviewing and making
recommendations on matters involving the general operation of the
Board of Directors, including Board size and composition, and
committee composition and structure;
- •
- evaluating and
recommending to the Board of Directors nominees for each committee
of the Board of Directors;
- •
- annually facilitating
the assessment of the Board of Directors' performance as a whole
and of the individual directors, as required by applicable law,
regulations and the NYSE corporate governance listing
standards;
- •
- considering
nominations by stockholders of candidates for election to our Board
of Directors;
- •
- considering and
assessing the independence of members of our Board of
Directors;
11
Table of
Contents
- •
- developing, as
appropriate, a set of corporate governance principles, and
reviewing and recommending to our Board of Directors any changes to
such principles;
- •
- periodically
reviewing our policy statements; and
- •
- reviewing, at least
annually, the adequacy of its Corporate Governance Committee
Charter.
When evaluating
director candidates, the Corporate Governance Committee's objective
is to craft a Board composed of individuals with a broad and
diverse mix of backgrounds and experiences and possessing, as a
whole, all of the skills and expertise necessary to guide a company
like us in the prevailing business environment. The Corporate
Governance Committee uses the same criteria to assess all
candidates for director, regardless of who proposed the candidate.
The Corporate Governance Committee considers whether the candidate
possesses the following qualifications and qualities:
- •
- independence for
purposes of the NYSE rules and SEC rules and regulations, and a
record of honest and ethical conduct and personal integrity;
- •
- experience in the
healthcare, real estate and/or public real estate investment trust
industry or in finance, accounting, legal or other professional
disciplines;
- •
- ability to represent
the interests of all of our stockholders; and
- •
- ability to devote
time to the Board of Directors and to enhance their knowledge of
our industry.
The Corporate
Governance Committee met one time in 2019. A copy of the charter of
the Corporate Governance Committee is available on the investor
relations webpage of our website, http://investors.chct.reit. Our
Corporate Governance Guidelines and Code of Ethics and Business
Conduct are also available on the investor relations webpage of our
website, http://investors.chct.reit. If we
make any substantive amendment to the Code of Ethics and Business
Conduct or grant any waiver, including any implicit waiver, from a
provision of the Code of Ethics and Business Conduct to certain
executive officers, we are obligated to disclose the nature of such
amendment or waiver, the name of the person to whom any waiver was
granted, and the date of waiver on our website or in a report on
Form 8-K filed with the SEC. Since the Company's inception,
there have been no such amendments or waivers.
The current
members of the Board propose nominees for election to the Board. In
addition, the Corporate Governance Committee will also consider
candidates that stockholders and others recommend. Stockholder
recommendations should be addressed to: W. Page Barnes, Corporate
Secretary, 3326 Aspen Grove Drive, Suite 150, Franklin,
Tennessee 37067. Your recommendations must be submitted to us no
earlier than October 21, 2020, nor later than 5:00 p.m.,
Eastern Time, on November 20, 2020, for consideration as a
possible nominee for election to the Board at our 2021 annual
meeting.
The Board has
not adopted a formal procedure that you must follow to send
communications to it, but it does have informal procedures,
described below, which it believes adequately facilitate
stockholder and other interested party communications with the
Board. Stockholders and other interested parties can send
communications to the Board by contacting W. Page Barnes, our
Corporate Secretary, in one of the following ways:
- •
- By writing to
Community Healthcare Trust Incorporated, 3326 Aspen Grove Drive,
Suite 150, Franklin, Tennessee, 37067, Attention: Corporate
Secretary;
- •
- By e-mail to
investorrelations@chct.reit; or
- •
- By phone at
615-771-3052.
12
Table of
Contents
If you request
information or ask questions that can be more efficiently addressed
by management, Mr. Barnes will respond to your questions
instead of the Board. He will forward to the Audit Committee any
communication concerning employee fraud or accounting matters and
will forward to the full Board any communication relating to
corporate governance or those requiring action by the Board of
Directors. A stockholder may communicate directly with
Mr. Gardner, the lead independent director, by sending a
confidential letter addressed to his attention at 3326 Aspen Grove
Drive, Suite 150, Franklin, Tennessee, 37067.
Director Compensation
The
Compensation Committee recommends the compensation for our
non-employee directors; our full Board approves or modifies the
recommendation. Any modifications are implemented after the annual
meeting. Directors who are also employees, currently only
Mr. Wallace, receive no additional compensation for their
service as a director, but are reimbursed for any direct board
related expenses. Annual compensation of non-employee directors may
be a combination of cash and restricted stock at levels set by the
Compensation Committee.
Cash compensation
Each
non-employee director receives an annual retainer, and chairpersons
of our board committees and the lead independent director receives
additional annual retainers. The annual retainers are payable after
each annual meeting of our stockholders. The current annual cash
retainer for service on our Board of Directors is $40,000 but may
be adjusted by the Compensation Committee based on an evaluation of
director compensation at peer companies. Additionally, the
chairpersons of the Audit Committee, the Compensation Committee and
the Corporate Governance Committee receive additional annual
retainers of $15,000, $10,000 and $10,000, respectively, and our
lead independent director receives an additional annual retainer of
$17,500. The Compensation Committee has not retained an independent
compensation consultant to advise it with respect to director
compensation of the Company since 2018. The most recent time the
Board increased the compensation of our non-employee directors for
their service on, and in positions on Committees of, the Board of
Directors was in February 2018, effective in May 2018.
Each year,
non-employee directors may elect to acquire shares of restricted
stock with all or a portion of each of their retainers. These
shares are issued 10 business days following the date of our annual
meeting of stockholders. The number of shares of restricted stock
to be acquired is determined by dividing the total amount of annual
retainer the director elected to use to acquire shares by the
average price of shares of common stock for the immediately
preceding 10 trading days. Pursuant to the Company's Amended and
Restated Alignment of Interest Program (the "Amended and Restated
Alignment of Interest Program"), each director who makes an
election to acquire shares of restricted stock with all or a
portion of their retainers will be awarded additional shares, at no
additional cost to the director, according to the following
multiples:
|
|
|
|
|
Duration of Restriction Period
|
|
Restriction
Multiple |
|
1 year
|
|
|
0.2x |
|
2 years
|
|
|
0.4x |
|
3 years
|
|
|
0.6x |
|
Accordingly,
for example, if a non-employee director elects to acquire shares of
restricted stock in lieu of cash compensation that is equivalent in
value to 1,000 shares of common stock and the director elected a
three-year restriction period for such restricted stock, the
non-employee director would receive the 1,000 shares of restricted
stock plus an award of 600 shares of restricted common stock for
electing to subject his or her restricted stock to a three-year
restriction period, resulting in a total
13
Table of
Contents
receipt of 1,600
shares of restricted stock, all of which would be subject to a
three-year cliff vesting schedule whereby no shares vest until the
third anniversary of the date of grant, at which time 100% of the
shares of restricted stock will vest.
The restriction
period subjects the shares purchased by the director and the
additional shares awarded by the Company to the risk of forfeiture
in the event that a director voluntarily resigns or is removed by
the stockholders prior to the vesting of these shares. All unvested
shares will be forfeited if such non-employee director voluntarily
resigns or is removed by the stockholders for any reason prior to
vesting. During the restriction periods described above, the
restricted shares may not be sold, assigned, pledged, or otherwise
transferred. Subject to the risk of forfeiture and transfer
restrictions, non-employee directors have all rights as
stockholders with respect to restricted shares, including the right
to vote and receive dividends or other distributions on such
shares.
Stock Awards
Each
non-employee director is also awarded an annual grant of shares of
restricted stock. Our goal is to have a minimum of 60% to 75% of
the aggregate total compensation for our non-employee directors
paid in the form of restricted stock having a restriction period of
up to three years. Directors are not entitled to receive additional
shares through a restriction multiple for these awards.
For 2019, each
non-employee director received an annual equity award of restricted
stock with an aggregate market value of $75,000 at the conclusion
of the 2019 annual stockholders' meeting. These shares are subject
to a three-year cliff vesting schedule whereby no shares vest until
the third anniversary of the date of grant, at which time 100% of
the shares of restricted stock will vest.
2019 Director Compensation
The following
table sets forth compensation paid during 2019 to each of our
non-employee directors:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fees Earned or Paid |
|
|
|
|
|
|
|
Name(1)
|
|
Fees Paid
in Cash |
|
Fees Paid
in Stock(2) |
|
Stock
Awards(3) |
|
All Other
Compensation |
|
Total |
|
Alan Gardner
|
|
$ |
— |
|
$ |
57,500 |
|
$ |
112,148 |
|
$ |
— |
|
$ |
169,648 |
|
Claire Gulmi
|
|
$ |
— |
|
$ |
50,000 |
|
$ |
107,322 |
|
$ |
— |
|
$ |
157,322 |
|
Robert Hensley
|
|
$ |
15,000 |
|
$ |
40,000 |
|
$ |
100,848 |
|
$ |
— |
|
$ |
155,848 |
|
Lawrence Van Horn
|
|
$ |
— |
|
$ |
50,000 |
|
$ |
107,322 |
|
$ |
— |
|
$ |
157,322 |
|
- (1)
- Mr. Wallace is
our other director and is also a full-time employee whose
compensation is discussed below under the section titled "Executive
Officers" and "Summary Compensation Table." Mr. Wallace
receives no additional compensation for his service as a
director.
- (2)
- This column
represents non-employee director annual retainer and additional
annual retainer amounts, approximately 93% of which was paid in
shares of our restricted common stock in lieu of cash. All of the
shares are subject to a three-year cliff vesting schedule whereby
no shares vest until the third anniversary of the date of grant, at
which time 100% of the shares of restricted stock will vest,
subject to the director's continuing service as a director of the
Company.
- (3)
- Represents the grant
date fair value computed in accordance with FASB ASC Topic 718 of
awards of restricted stock to the non-employee directors under the
2014 Incentive Plan, or the 2019 Director Awards. The dollar value
of the 2019 Director Awards was based upon the grant date price of
our common stock, which was $37.18 on May 16, 2019. This
column also includes the amount of the grant date value of the
shares received in accordance with restriction multiples with
respect to the deferral of director retainer amounts based on the
price of our common stock of
14
Table of
Contents
$39.13 on the
determination date, May 31, 2019. All of the shares are
subject to a three-year cliff vesting schedule whereby no shares
vest until the third anniversary of the date of grant, at which
time 100% of the shares of restricted stock will vest, subject to
the director's continuing service as a director of the
Company.
We also reimburse our
directors for expenses they incur in connection with their service
on our Board, such as director education, travel and lodging
expenses.
15
Table of
Contents
COMPENSATION DISCUSSION AND
ANALYSIS
This
Compensation Discussion and Analysis describes the material
elements of the Company's named executive officer compensation
program and analyzes the compensation decisions made for our
executive officers included in the Summary Compensation Table
beginning on page 31 (the "named executive
officers").
2019 Named Executive Officers
Our named
executive officers for 2019 were:
Timothy Wallace—Chief
Executive Officer and President
David Dupuy—Chief
Financial Officer and Executive Vice President
Page Barnes—Chief
Operating Officer and Executive Vice President
Leigh Ann Stach—Chief
Accounting Officer and Executive Vice President
Because only
four individuals served as our executive officers at any time
during 2019, we have only four named executive officers for
2019.
2019 Highlights
We believe that
2019 was a successful year for the Company. Our named executive
officers continued to execute our business plan during 2019 and
built upon our operating and financial performance results achieved
since we became a publicly traded company after our initial public
offering in May 2015.
Our operating
and financial performance highlights in 2019 included:
- •
- Achieving net income
of $0.37 per diluted share, FFO of $1.67 per diluted share and AFFO
of $1.77 per diluted share, compared to net income of $0.19 per
diluted share, FFO of $1.53 per diluted share and AFFO of $1.62 per
diluted share in 2018;
- •
- Acquiring fifteen
(15) properties for an aggregate purchase price of
approximately $152.0 million with estimated yields ranging
from 9.02% to 11.00%. These properties were approximately 99.5%
leased with lease expirations through 2034;
- •
- Raising gross
proceeds of $107.3 million under our at-the-market offering
program;
- •
- Maintaining low
leverage levels with a debt-to-total capitalization ratio (debt
plus stockholders' equity plus accumulated depreciation) of
approximately 31.1%; and
- •
- Generating a
year-over-year total stockholder return of approximately 48%
(versus approximately 27% for the NAREIT All Equity REIT Index) for
the year ended December 31, 2019.
Reconciliations
of FFO and AFFO are provided in Appendix A beginning on
page 46 of this Proxy Statement.
Comprehensive Compensation Policy
We believe that
the compensation of our executive officers aligns their interests
with those of the stockholders in a way that encourages prudent
decision-making, links compensation to our overall performance,
provides a competitive level of total compensation necessary to
attract and retain talented and experienced executive officers and
motivates the executive officers to contribute to our
success.
16
Table of
Contents
All of our
executive officers are eligible to receive performance-based
compensation under the 2014 Incentive Plan as amended by Amendment
No. 1 to the 2014 Incentive Plan, Amendment No. 2 to the
2014 Incentive Plan, and Amendment No. 3 to the 2014 Incentive
Plan (as so amended, our 2014 Incentive Plan).
We use a
combination of allowing the acquisition shares of restricted stock
in connection with grants of restricted stock as the primary means
of delivering long-term compensation to our executive officers.
Shares of restricted stock are forfeitable until the lapse of the
applicable restrictions. We believe that restricted stock with long
vesting periods align the interests of executive officers and
stockholders and provide strong incentives to our executive
officers to achieve long-term growth in our business, grow the
value of our common stock and maintain or increase our
dividends.
The executive
officers personally benefit from these efforts through their
restricted stock, which pay dividends at the same rate as
unrestricted stock and increase in value as the value of
unrestricted stock increases. However, the Company's executive
officers essentially have to earn this equity compensation twice:
the first time through their efforts to meet the initial
performance criteria necessary to receive the restricted stock; and
the second time by continued service through the at-risk vesting
period.
Substantially
all of our executive officers' compensation is tied to the value of
our common stock since the officers have elected to receive
restricted stock in lieu of cash compensation. Therefore, if we
have superior long-term operating performance, our executive
officers, through their restricted stock, will eventually receive
more value, due to increases in the price of our common stock, than
if they had been paid in cash. Conversely, if we have inferior
long-term operating performance, our executive officers through
their restricted stock will eventually receive less value, due to
decreases in the price of our common stock, than if they had been
paid in cash.
Our
Compensation Committee determines the restrictions for each award
granted pursuant to the 2014 Incentive Plan. Restrictions on the
restricted stock may include time-based restrictions, the
achievement of specific performance goals or the occurrence of a
specific event. Vesting of restricted stock will generally be
subject to cliff vesting periods ranging from three to eight years
and will be conditioned upon the participant's continued
employment, among other restrictions that may apply.
If the
performance goals are not achieved or the time-based restrictions
do not lapse within the time period provided in the award
agreement, the participant will forfeit his or her unvested
restricted stock.
Compensation Methodology
Compensation Committee's Governance
The Board
established the Compensation Committee to carry out the Board's
responsibilities to administer our compensation programs. The
Compensation Committee has the final decision-making authority for
the compensation of our executive officers. The Compensation
Committee operates under a written charter adopted by the
Compensation Committee and approved by the Board. The charter is
available in the investor relations section of our website
(http://investors.chct.reit).
Our
Compensation Committee has independent authority to engage outside
consultants and obtain input from external advisers as well as our
management team or other employees.
The
Compensation Committee may retain any independent counsel, experts
or advisors that it believes to be desirable and appropriate. The
Compensation Committee may also use the services of the Company's
regular legal counsel or other advisors to the Company. The
Compensation Committee undertakes an independent assessment prior
to retaining or otherwise selecting any independent counsel,
compensation consultant, search firm, expert or other advisor that
will provide advice to it,
17
Table of
Contents
taking such factors
into account and as otherwise may be required by the NYSE from time
to time. On at least an annual basis, the Compensation Committee
evaluates whether any work by any compensation consultant to it
raised any conflict of interest.
The
Compensation Committee retained FPL Associates ("FPL") as its
independent compensation consultant in 2019 to advise it regarding
market trends and practices in executive compensation and with
respect to specific compensation decisions. The Compensation
Committee expects to meet at least annually with a compensation
consultant to discuss executive compensation trends. The consultant
may also attend Compensation Committee meetings periodically. FPL
met with the chair of the Compensation Committee in 2019, during
and in which it provided a review of recent trends and developments
in executive compensation practices within the Company's industry
and in general. FPL received a fee of $20,000 for its compensation
consulting services provided to the Compensation Committee in 2019
with respect to executive compensation.
Our Chief
Executive Officer typically attends Compensation Committee
meetings, except for executive sessions (unless specifically
requested by the Compensation Committee to be present). No
executive officer attends an executive session at which his or her
compensation is considered. Our Chief Executive Officer may provide
recommendations with respect to compensation for the executive
officers other than himself. The Compensation Committee considers
these recommendations, but may approve, reject or adjust them as it
deems appropriate.
Compensation Risk Assessment
The
Compensation Committee believes its compensation policies and
practices do not promote excessive risk-taking and are not likely
to have a material adverse effect on the Company. In particular,
the Compensation Committee believes that the following factors
mitigate excessive risk-taking by the named executive
officers:
- •
- The use of restricted
stock, with long vesting periods during which the stock cannot be
sold, provides an incentive to the named executive officers to make
decisions that contribute to long-term growth of the Company, the
stability of NOI, and the delivery of dividends to
stockholders.
- •
- The maximum potential
cash and stock incentive payments are capped at levels such that
total compensation would remain comparable within the peer
group.
- •
- The Compensation
Committee retains broad discretionary authority to adjust annual
awards and payments, which further mitigates risks associated with
the Company's compensation plans and policies.
Peer Group
For 2019, the
Compensation Committee, based on FPL's recommendation, used the
companies listed below as the peer group against which to measure
the Company's relative one-year and three-year TSR performance. The
peer group is selected each year in accordance with the Amended and
Restated Executive Officer Incentive Program. The Amended and
Restated Executive Officer Incentive Program provides a mechanism
for determining the peer group, which the Compensation Committee
believes provides for the most closely comparable companies with
respect to market capitalization and appropriate pay levels. In
determining our peer group, all publicly-traded equity REITs are
sorted by market capitalization. Additional criteria used can
include industry segment, asset base, externally/internally managed
and years of operating history. The Compensation Committee, based
on FPL's recommendations, makes discretionary adjustments to
include or exclude companies in
18
Table of
Contents
the peer group to
capture the Company's closest competitors and to adjust for events
such as mergers that might occur during the period. The following
companies comprised the peer group for 2019:
|
|
|
Physicians Realty
Trust |
|
One Liberty
Properties, Inc. |
National Health Investors, Inc. |
|
CatchMark Timber Trust, Inc. |
LTC Properties, Inc. |
|
MedEquities Realty Trust, Inc. |
CareTrust REIT, Inc. |
|
Sotherly Hotels, Inc. |
Easterly Government
Properties, Inc. |
|
Wheeler Real Estate Investment
Trust, Inc. |
City Office REIT, Inc. |
|
Plymouth Industrial REIT, Inc. |
The
Compensation Committee determines the peer group each year and
compares the compensation of the peer group for the year preceding
the applicable year.
Material Components of Compensation
Elements of Pay
In 2019, the
Company's compensation program for its named executive officers
consisted of the following key elements:
- •
- Annual base
salaries;
- •
- Elective acquisition
of restricted shares with corresponding restricted share grants,
allowing named executive officers to increase their ownership
portion in the Company;
- •
- Performance based
awards of cash, stock, or a combination of both; and
- •
- Perquisites and
retirement benefits.
Annual Base Salary
Each of our
named executive officers has an employment agreement that
establishes his or her base salary. Adjustments to base salary are
determined by the Compensation Committee and are based upon a
review of a variety of factors, including:
- •
- individual and
Company performance, measured against quantitative and qualitative
goals, such as growth, asset quality and other matters;
- •
- duties and
responsibilities, as well as the named executive officer's
experience;
- •
- the types and amount
of each element of compensation to be paid to the named executive
officer; and
- •
- salary levels of
persons holding similar positions at companies included in our peer
group.
19
Table of
Contents
The base salary
of the Company's named executive officers for 2020 and 2019, before
any elective deferral of cash for restricted stock, is as
follows:
|
|
|
|
|
|
|
|
Named Executive Officer
|
|
2020
Base Salary |
|
2019
Base Salary |
|
Timothy G. Wallace
|
|
$ |
645,000 |
|
$ |
540,000 |
|
Chief Executive Officer and
|
|
|
|
|
|
|
|
President
|
|
|
|
|
|
|
|
David H. Dupuy
|
|
$ |
392,000 |
|
$ |
233,333 |
(1) |
Executive Vice President and
|
|
|
|
|
|
|
|
Chief Financial Officer
|
|
|
|
|
|
|
|
W. Page Barnes
|
|
$ |
370,400 |
|
$ |
328,000 |
|
Executive Vice President and
|
|
|
|
|
|
|
|
Chief Operating Officer
|
|
|
|
|
|
|
|
Leigh Ann Stach
|
|
$ |
326,800 |
|
$ |
266,000 |
|
Executive Vice President and
|
|
|
|
|
|
|
|
Chief Accounting Officer
|
|
|
|
|
|
|
|
- (1)
- Mr. Dupuy's base
salary for 2019 is for the period beginning May 1, 2019
through December 31, 2019.
Pursuant to the
Amended and Restated Alignment of Interest Program described below,
executive officers may elect to utilize any cash compensation they
receive to acquire shares of restricted stock. In the event that an
executive officer elects to acquire shares of restricted stock,
rather than cash compensation, the officer will be awarded shares
of restricted stock pursuant to the Amended and Restated Alignment
of Interest Program, subject to a three-, five-, or eight- year
cliff-vesting schedule, depending on the officer's election. Each
executive officer who makes this election will be awarded the
additional restricted common stock award at no cost to the officer,
according to the multiple-based formula set forth on page 21
of this proxy statement.
2014 Incentive Plan
Awards may be
made in the form of restricted stock or cash under our 2014
Incentive Plan. The purposes of the 2014 Incentive Plan are to
attract and retain qualified persons upon whom, in large measure,
our sustained progress, growth and profitability depend, to
motivate the participants to achieve long-term Company goals and to
more closely align the participants' interests with those of our
other stockholders by providing them with a proprietary interest in
our growth and performance.
Our executive
officers, non-executive officers, employees, consultants and
non-employee directors may be eligible to participate in the 2014
Incentive Plan as determined by the Compensation Committee. As of
March 6, 2020, the number of shares of our common stock
available for issuance under the 2014 Incentive Plan is
719,870.
The 2014
Incentive Plan is administered by our Compensation Committee, which
interprets the 2014 Incentive Plan and has broad discretion to
select the eligible persons to whom awards will be granted, as well
as the type, size and terms and conditions of each award, including
the amount of cash or number of shares subject to awards and the
expiration date of, and the vesting schedule or other restrictions
(including, without limitation, restrictive covenants) applicable
to, awards. However, during a calendar year, no participant may
receive awards intended to comply with the performance-based
compensation requirements of Section 162(m) of the Internal
Revenue Code of 1986, as amended (the "Code"), which exceed 150,000
shares of common stock.
20
Table of
Contents
Unless the 2014
Incentive Plan is terminated earlier by our Board of Directors, the
2014 Incentive Plan will automatically terminate on March 31,
2024. Awards granted before the termination of the 2014 Incentive
Plan may extend beyond that date in accordance with their
terms.
The two
distinct programs applicable to executive officers under the 2014
Incentive Plan are the Amended and Restated Alignment of Interest
Program and the Amended and Restated Executive Officer Incentive
Program. In addition, we believe it is in the best interests of our
stockholders to encourage all executive officers to increase their
equity position in the Company to promote share ownership and
further align employee and stockholder interests and have therefore
adopted stock ownership guidelines with respect to our executive
officers and directors.
Amended and Restated Alignment of Interest Program
The Company's
Amended and Restated Alignment of Interest Program, under the 2014
Incentive Plan, is designed to provide the Company's executive
officers with an incentive to remain with the Company and to
incentivize long-term growth and profitability. The original
Alignment of Interest Program was amended in November 2016 by the
Company's Board of Directors to, among other items, reserve 500,000
shares of the Company's common stock to be acquired by employees
and directors pursuant to elections to acquire restricted stock
with their compensation.
Pursuant to the
Amended and Restated Alignment of Interest Program, executive
officers may elect to acquire restricted stock in lieu of up to
100% of any compensation otherwise payable in cash under their
employment agreements. The executive officer must elect his or her
participation level and the applicable vesting period for the
upcoming year no later than December 31 of the then-current
year. The number of shares of restricted stock to be acquired will
be determined as of January 15 of the year following the
election or, if such date is not a trading day, on the trading day
immediately before January 15 by dividing the total of the
named executive officer's elected deferred salary, cash bonus or
other compensation by the average price of our common stock for the
10 trading days immediately preceding the determination date. If
the dollar amount of any reduced salary, cash bonus or other
compensation has not been determined by January 15, then the
determination date will be the 10th business day following the
date on which the amount of such cash compensation is fixed and
determined. Payments of restricted stock in lieu of compensation
otherwise payable in cash will be made thereafter.
To the extent
an executive officer elects to acquire stock in lieu of cash
compensation, the executive officer is entitled to receive an award
of restricted stock pursuant to the Amended and Restated Alignment
of Interest Program, subject to a three, five or eight-year cliff
vesting schedule, depending on each executive officer's election.
Each executive officer who makes this election is awarded the stock
award at no cost to the executive officer, according to the
following multiple-based formula:
|
|
|
|
|
Duration of Restriction Period
|
|
Restriction
Multiple |
|
3 years
|
|
|
0.3x |
|
5 years
|
|
|
0.5x |
|
8 years
|
|
|
1.0x |
|
Accordingly,
for example, if an executive officer elects to acquire shares of
restricted stock in lieu of cash compensation that is equivalent in
value to 1,000 shares of common stock and the executive officer
elected an eight-year restriction period for such restricted stock,
the executive officer would receive the 1,000 shares of restricted
stock plus an award of 1,000 shares of restricted stock for
electing to subject his or her restricted stock to an eight-year
restriction period, resulting in a total receipt of 2,000 shares of
restricted stock, all of which would be subject to an eight-year
cliff vesting schedule
21
Table of
Contents
whereby no shares vest
until the eighth anniversary of the date of grant, at which time
100% of the shares of restricted stock will vest.
The restriction
period subjects the shares acquired by the executive officer and
the additional shares awarded by the Company to the risk of
forfeiture in the event that the executive officer voluntarily
terminates employment or is terminated for cause from employment
with the Company, as those terms are described below, prior to the
vesting of the shares. All unvested shares will be forfeited if
such executive officer voluntarily terminates employment or is
terminated for cause prior to vesting. During the restriction
periods described above, the restricted shares may not be sold,
assigned, pledged or otherwise transferred. Subject to the risk of
forfeiture and transfer restrictions, executive officers have all
rights as stockholders with respect to restricted shares, including
the right to vote and receive dividends or other distributions on
such shares.
All
executive officers have elected to take 100% of their base salary
and acquire shares of restricted stock since the Company's initial
public offering, or since joining the Company as an executive
officer.
Amended and Restated Executive Officer Incentive
Program
We also have an
Amended and Restated Executive Officer Incentive Program under the
2014 Incentive Plan pursuant to which our executive officers may
earn performance-based awards in the form of cash and/or restricted
stock. Any awards under the Amended and Restated Executive Officer
Incentive Program and its interpretation and operation are subject
to the discretion of the Compensation Committee.
The Amended and
Restated Executive Officer Incentive Program is designed to
directly link compensation to performance. The Company believes
that the combination of operating metrics and shareholder return
provides the best incentive structure for the growth of long-term
shareholder value.
Through the
Amended and Restated Executive Officer Incentive Program, our named
executive officers are rewarded for attaining targeted individual
performance, targeted company performance and relative TSR
performance. For 2019, almost 80% of the aggregate total
compensation for our named executive officers was paid in the form
of performance-based compensation, all of which was in restricted
stock with cliff vesting periods of eight years.
The
Compensation Committee believes that this further demonstrates
alignment of the interests of our named executive officers with
that of the Company's shareholders.
Individual Performance Awards
The
Compensation Committee grants awards of cash, stock, or a
combination of both under the 2014 Incentive Plan based on each
executive officer's individual performance, and may determine all
terms of the award, including to whom, and the time or times at
which, individual performance awards may be granted, the number of
shares, units or other rights subject to each individual
performance award, the exercise, base or purchase price of such
individual performance award (if any), the time or times at which
such individual performance award will become vested, exercisable
or payable, the performance criteria, goals and other conditions of
the individual performance award, and the duration of the
individual performance award.
In 2019, the
Compensation Committee approved the payment of cash individual
performance awards to the Company's executive officers in the
aggregate of approximately $476,933. The executive officers each
elected to acquire restricted shares of common stock in lieu of the
cash bonuses, which based on their elections are subject to an
eight-year cliff vesting schedule. Based on the eight-year
restriction period elected, the executive officers acquired an
aggregate of 11,222 shares of restricted stock in lieu of their
cash bonuses and were granted 11,221 additional shares based on the
restriction period elected.
All
executive officers have elected to take 100% of their bonuses and
acquire shares of restricted stock since the Company's initial
public offering, or since joining the Company as an executive
officer.
22
Table of
Contents
Company Performance Awards
The
Compensation Committee judges the Company's performance under the
Amended and Restated Executive Officer Incentive Program against
targeted metrics set in advance by the Compensation
Committee.
Company
Performance Awards ("CPA") may be issued under the 2014 Incentive
Plan based on specific Company performance targets. The
Compensation Committee may determine, in its discretion, the
particular financial and/or operating metrics to be targeted, which
may include, but are not limited to AFFO, payout percentages, etc.
The measurement period is four consecutive quarters ending on
June 30 of each year or such date as the Compensation
Committee may determine.
The
Compensation Committee anticipates that participants will have the
opportunity to earn Company Performance Awards each year. The
Company will generally target a maximum of two performance metrics
during any given measurement period and a maximum combined award
for all such metrics of up to 50% of such participant's base
salary.
The Company
currently combines several performance metrics and is based on a
sliding scale of the attainment of AFFO required to reach
prescribed payout ratios assuming an increasing dividend
rate.
To date, no
awards have been made by the Compensation Committee pursuant to a
Company Performance Award. To the extent a Company Performance
Award is earned, any cash award will be available for participation
in the Amended and Restated Alignment of Interest
Program.
Total Shareholder Return Awards
Total
Shareholder Return Awards ("TSRA") are based on the Company's total
shareholder return, as measured against the Peer Group. The
criteria for awarding TSRAs are the Company's relative total
shareholder return performance measured as a percentile, as
compared to the total shareholder returns of the companies in the
Peer Group. The current measurement period is four and twelve
consecutive quarters ending June 30 of each year.
The Company
generally targets a maximum TSRA for each executive officer of up
to 200% of such executive officer's base salary. Executive officers
have the opportunity to earn TSRAs each year based on 1-year total
shareholder return and 3-year total shareholder return. TSRAs are
in the form of restricted stock with an eight-year cliff vesting
period and are not available for the Amended and Restated Alignment
of Interest Program. The TSRA percentages range from 0% up to 100%
of base salary depending on the relative total shareholder return
versus the members of the peer group. The number of shares are
determined as of June 30th by dividing the total of the
executive officer's TSRA by the average closing price of the common
stock for the 10 trading days immediately preceding
June 30.
The Company
granted TSRAs in the form of restricted stock under the Amended and
Restated Executive Officer Incentive Program to our executive
officers in 2019 in the aggregate of 66,419 shares of common stock
which will cliff vest in eight years.
Perquisites
The Company
provides its executive officers with perquisites that it believes
are reasonable, competitive and consistent with the Company's
compensation program for all employees. The Company believes that
such perquisites help the Company to retain its personnel. In 2019,
these perquisites included matching contributions in each
participating executive's 401(k) and a contribution for each
participating executive's health savings account (HSA), calculated
in the same manner as for all employees, as well as moving and
relocation expenses for Mr. Dupuy.
23
Table of
Contents
Retirement Benefits
All named
executive officers are eligible to participate in the Company's
401(k) plan, pursuant to which each participant may contribute up
to the annual maximum allowed under IRS regulations ($19,000 for
2019). All eligible participants over the age of 50 may also
contribute an additional $6,000 per year to the plan in the form of
catch-up contributions. The Company provides a matching
contribution of up to an annual maximum three and one-half percent
for the first six percent of base salary contributed to the
plan.
Compensation Governance Practices
Anti-Hedging Policy
The Company
prohibits the hedging of Company securities by its executive
officers and directors. None of the executive officers or directors
have entered into any hedging arrangements with respect to the
Company's securities. In addition, restricted stock may not be
sold, assigned, pledged or otherwise transferred.
At Risk Compensation
Since the
Company's initial public offering or joining Company, as
applicable, all named executive officers have elected to take 100%
of their compensation in restricted stock of the Company that
cliff-vests in 8-years. Until such time that those shares vest,
each named executive officer is at risk of forfeiting those shares,
as well as losing value of the shares should events occur,
including management errors, that negatively impact the financial
results or performance of the Company.
We believe this
compensation program aligns executive management with our
stockholders, encourages appropriate long-term decision-making and
effectively rewards or punishes executive management for their
decisions made.
Stock Ownership Guidelines
We believe that
it is in the best interests of our stockholders to encourage all
executive officers and directors to increase their equity position
in the Company to promote share ownership and further align
stockholder interests with executive officers and directors.
Accordingly, as set forth in the table below, we have adopted stock
ownership guidelines applicable to our executive officers and
directors requiring each to hold common stock with a fair market
value equal to a multiple of each officer's then current base
salary or each non-employee director's then current annual
retainer, as applicable:
|
|
|
Position
|
|
Common Stock Ownership Multiple |
Chief Executive
Officer |
|
5x Current Base
Salary |
Executive Vice
President |
|
3x Current Base
Salary |
Non-Employee
Director |
|
3x Current Base
Annual Retainer |
The guidelines
provide that all owned stock, both restricted and unrestricted,
counts toward the ownership guidelines. All of our executive
officers and directors were in compliance with these guidelines as
of March 6, 2020.
Internal Revenue Code Section 162(m)
Section 162(m)
of the Internal Revenue Code generally disallows a tax deduction to
public companies for compensation over $1 million paid to a
corporation's chief executive officer and the three other most
highly compensated executive officers (excluding the chief
financial officer). In 2017 and prior tax years, qualifying
performance-based compensation was not subject to the deduction
limit if certain requirements were met. Effective for tax years
beginning on January 1, 2018, the tax reform
24
Table of
Contents
legislation informally
known as the Tax Cuts and Jobs Act of 2017 repeals the
performance-based compensation exception to the Section 162(m)
$1 million deduction limit. The Company's tax deduction for
compensation expense in 2019 was not limited pursuant to
Section 162(m) because no applicable officer's compensation,
as determined for federal income tax purposes, exceeded the
applicable limit. As a qualifying REIT, the Company does not pay
federal income tax; therefore, the future unavailability of the
Section 162(m) compensation deduction is not expected to
result in any increase in the Company's federal income tax
obligations.
CEO Pay Ratio
Pursuant to
rules adopted by the SEC under the Dodd-Frank Act, the Company is
required to disclose the ratio of the annual total compensation for
its CEO to the median annual total compensation for its employees
other than the CEO. The Company identified the median employee by
examining its payroll records for 2019 for all individuals other
than the CEO that were employed by the Company at December 31,
2019. Compensation for employees that began employment during the
year was annualized based on rate of pay applied to a full
year.
As of
December 31, 2019, the Company had 25 employees. These
employees are all employed at the Company's corporate office and
are comprised of executive and non-executive officers, asset
management, accountants, and various other roles and
responsibilities. At December 31, 2019, the Company identified
its median employee as one making $105,761 per year. For 2019, the
Company's CEO, Mr. Wallace, had an annual total compensation
of $2,595,964. This amount is comprised of several components, as
reflected in the Summary Compensation Table beginning on
page 31. Additional information concerning Mr. Wallace's
total compensation is provided in the Compensation Discussion and
Analysis section beginning on page 16 and in the Executive
Officers section beginning on page 28.
The ratio of
CEO pay to median employee pay at December 31, 2019 was 25:1.
The table below illustrates the details of the
calculation.
|
|
|
|
|
|
|
|
|
|
CEO to Median Employee Pay Ratio |
|
Pay
|
|
Chief Executive Officer
and President |
|
Median Employee |
|
Salary
|
|
|
|
|
|
|
|
Cash
|
|
$ |
— |
|
$ |
92,000 |
|
Salary stock
|
|
$ |
572,278 |
|
$ |
— |
|
Bonus
|
|
|
|
|
|
|
|
Cash
|
|
$ |
— |
|
$ |
10,000 |
|
Bonus stock
|
|
$ |
220,036 |
|
$ |
— |
|
Alignment of Interest Stock
|
|
$ |
756,000 |
|
$ |
— |
|
1-Year Total Shareholder Return Stock
|
|
$ |
444,358 |
|
$ |
— |
|
3-Year Total Shareholder Return Stock
|
|
$ |
592,492 |
|
$ |
— |
|
All Other Compensation
|
|
$ |
10,800 |
|
$ |
3,761 |
|
|
|
|
|
|
|
|
|
Total
|
|
$ |
2,595,964 |
|
$ |
105,761 |
|
CEO to Media Employee Pay Ratio
|
|
|
|
|
|
25:1 |
|
Termination, Severance and Change-in-Control
Arrangements
Under the terms
of the Company's compensation plans and its employment agreements
with the named executive officers, if employment is terminated for
any reason other than for cause, change-in-control or death or
disability, the named executive officer is entitled to receive all
accrued salary, bonus compensation, if any, to the extent earned,
whether or not vested without regard to such termination (other
than defined contribution plan or profit sharing plan benefits
which will be paid in accordance with the applicable plan), any
benefits under any plans of the Company in which the
named
25
Table of
Contents
executive officer is a
participant to the full extent of the named executive officer's
rights under such plans, full vesting of all awards granted to the
named executive officer under the 2014 Incentive Plan, accrued
vacation pay and any appropriate business expenses incurred by the
named executive officer in connection with his or her duties
hereunder, all to the date of termination. In addition, the named
executive officer will receive as severance compensation his or her
base salary (at the rate payable at the time of such termination),
for a period of 36 months, with respect to Mr. Wallace,
and 12 months, with respect to Mr. Dupuy, Mr. Barnes
and Ms. Stach, from the date of such termination; provided,
however, that if the named executive officer is employed by a new
employer during such period, the severance compensation payable to
the named executive officer during such period will be reduced by
the amount of compensation that the named executive officer is
receiving from the new employer. However, the named executive
officer is under no obligation to mitigate the amount owed the
named executive officer by seeking other employment or otherwise.
In addition to the severance payment, the named executive officer
will be paid an amount equal to the greater of: (i) two times
the average annual cash bonus, if any, earned by the named
executive officer in the two years immediately preceding the date
of termination, without regard to any elective income deferral or
conversion of such bonus into stock or any other non-cash
consideration; and (ii) two times the product of the named
executive officer's base salary and 0.67 with respect to
Mr. Wallace, and 0.33 with respect to Mr. Dupuy,
Mr. Barnes and Ms. Stach. Each named executive officer
will be entitled to accelerated vesting of any accrued benefit
under each deferred compensation plan. If a named executive officer
is terminated for disability, the terminated named executive
officer will receive the benefits described above, all to the date
of termination, with the exception of medical and dental benefits,
if any, which shall continue at the Company's expense through the
then current one-year term of the employment agreement. If a named
executive officer's employment terminates due to death, the
terminated named executive officer's estate will receive the
benefits described above.
The severance
payment in the event of a change in control will consist of:
(1) three times the terminated officer's annual base salary
(at the rate payable at the time of such termination), and
(2) an amount equal to the greater of: (i) two times the
average annual cash bonus, if any, earned by the terminated officer
in the two years immediately preceding the date of termination,
without regard to any elective income deferral or conversion of
such bonus into stock or any other non-cash consideration; and
(ii) two times the product of the terminated officer's base
salary and 0.67 with respect to Mr. Wallace, and 0.33 with
respect to Mr. Dupuy, Mr. Barnes and Ms. Stach. Such
severance compensation shall be paid in a lump sum promptly after
the date of such termination, and in no event later than two and a
half months after the end of the year in which such termination
occurs. If the payments due to the change-in-control result in an
excise tax to the terminated officer, under Section 4999 of
the Code, all change-in-control payments to the terminated officer
may be limited to an amount that is less than 300% of his or her
average annual compensation. This limit would not apply in the
event that the terminated officer's net after-tax benefits are
greater after considering the effect of the excise tax.
26
Table of
Contents
COMPENSATION COMMITTEE REPORT
The
following Compensation Committee Report does not constitute
soliciting material and should not be deemed filed or incorporated
by reference into any other Company filing under the Securities Act
or the Exchange Act, except to the extent the Company specifically
incorporates this Report by reference therein.
The
Compensation Committee has reviewed and discussed the Compensation
Discussion and Analysis contained in this Proxy Statement with
management of the Company and, based on such review and
discussions, the Compensation Committee has recommended to the
Board of Directors that the Compensation Discussion and Analysis be
included in this Proxy Statement.
Members of the
Compensation Committee:
Claire Gulmi
(Chair)
Alan Gardner
Lawrence Van Horn
COMPENSATION COMMITTEE INTERLOCKS AND INSIDER
PARTICIPATION
The members of
the Compensation Committee during 2019 were Claire Gulmi (Chair),
Alan Gardner, and Lawrence Van Horn. In 2019, no member of the
Compensation Committee was an officer or employee of the Company or
any of its subsidiaries or was formerly an officer of the Company
or any of its subsidiaries, and no member had any relationship
requiring disclosure as a related person transaction under
applicable SEC regulations.
27
Table of
Contents
EXECUTIVE OFFICERS
The names,
ages, positions and business experience of our executive officers,
except for Mr. Wallace, are listed below. Because he is also a
member of our Board, information about Mr. Wallace appeared
previously under Proposal 1—Election of Directors beginning on
page 4. All of our executive officers serve at the discretion
of the Board and are parties to employment agreements.
|
|
|
|
|
Name
|
|
Age |
|
Position |
David H.
Dupuy |
|
51 |
|
Mr. Dupuy has
served as our Executive Vice President and Chief Financial Officer
since May 2019. From 2008 to 2019, Mr. Dupuy served as a
Managing Director, Healthcare Investment Banking Group at SunTrust
Robinson Humphrey. From 2004 to 2008, Mr. Dupuy served as a
Senior Vice President of the Healthcare Group at Bank of America.
From 2000 to 2004, Mr. Dupuy served as a Vice President and
Regional Director for KDA Holdings with responsibility for
consulting, financing, and development of outpatient medical
facilities. Previously, Mr. Dupuy served as Chief Financial
Officer and Founding Partner of LIFESIGNS Holdings, Inc., a
provider of diagnostic healthcare services, from 1997 to 2000.
Mr. Dupuy began his career in 1991 with Bank of America.
Mr. Dupuy holds a Bachelor of Arts in Business Administration
from Furman University and a Master of Business Administration from
the Owen School at Vanderbilt University. |
W. Page Barnes |
|
66 |
|
Mr. Barnes has served as our Executive Vice
President and Chief Operating Officer since May 1, 2019. Prior
to becoming Chief Operating Officer, Mr. Barnes served as our
Chief Financial Officer since the formation of our Company in March
2014. Mr. Barnes is responsible for financing and management
activities. Prior to joining our Company, from 2005 to 2013,
Mr. Barnes was a co-founder, Chief Financial Officer and
Executive Vice President—Chief Development Officer for Haven
Behavioral Healthcare where he was responsible for raising a
$100 million private equity investment, negotiating four
separate bank financings and the acquisition and/or development of
12 hospitals. From 1997 to 2005, Mr. Barnes served as Chief
Financial Officer then Senior Vice President—Finance for Ardent
Health Services and its predecessor Behavioral Healthcare
Corporation. Prior to Ardent, Mr. Barnes began a banking
career with AmSouth Bank in 1990 as a Commercial Real Estate
Relationship Manager and ended it in 1997 as Senior Vice President
and Manager of the Healthcare Banking Department. Mr. Barnes
holds a Bachelor of Science in Accounting from Auburn
University. |
28
Table of
Contents
|
|
|
|
|
Name
|
|
Age |
|
Position |
Leigh Ann
Stach |
|
53 |
|
Ms. Stach has
served as our Chief Accounting Officer since the formation of our
company in March 2014 and as Executive Vice President since May
2019. Prior to her appointment as Executive Vice President in May,
Ms. Stach served as our Vice President—Financial Reporting,
and Chief Accounting Officer. From 2005 to 2013, Ms. Stach
served as Vice President—Financial Reporting at HR where she had
responsibility for financial reporting and coordinating due
diligence materials for debt and equity offerings. In addition, she
brought EDGAR and XBRL filings in-house and provided oversight of
HR's compliance function and internal audit. Prior to that, from
1997 to 2005, Ms. Stach served as Vice President—Controller at
HR. From 1994 to 1997, Ms. Stach served as Assistant
Controller at HR. Prior to HR, from 1991 to 1994, Ms. Stach
was a senior accountant—financial reporting at HCA. She began her
career with Hospital Corporation of America in 1988 as an internal
auditor. Ms. Stach holds a Bachelor of Science in Accounting
from Western Kentucky University. |
Employment Agreements of our Named Executive
Officers
We have entered
into employment agreements with each of Mr. Wallace,
Mr. Dupuy, Mr. Barnes, and Ms. Stach, which became
effective on May 28, 2015 for Mr. Wallace,
Mr. Barnes, and Ms. Stach, and May 1, 2019 for
Mr. Dupuy. The initial term of each of Mr. Wallace's,
Mr. Barnes', and Ms. Stach's employment agreements were
through December 31, 2017, while the initial term of
Mr. Dupuy's employment agreement was through December 31,
2019. The term of each respective employment agreement
automatically renews for successive one-year terms on
December 31 of each calendar year. As amended on
January 3, 2020, the annual base salary of each of
Mr. Wallace, Mr. Dupuy, Mr. Barnes and
Ms. Stach under each of their employment agreements was
increased for fiscal year 2020 from $540,000 to $645,000, from
$350,000 to $392,000, from $328,000 to $370,400 and from $266,000
to $326,800, respectively. In addition, Mr. Dupuy is to be
awarded a grant of 5,000 shares of restricted common stock per year
for three years, which began on May 1, 2019, vesting equally
in 2027, 2028, and 2029.
On
March 11, 2019, the Company entered into an amended and
restated employment agreement with Mr. Barnes in connection
with his new role as Chief Operating Officer that became effective
on May 1, 2019. Other than related to Mr. Barnes' change
in role, the compensation terms and other material terms of
Mr. Barnes' employment with the Company remain unchanged. On
May 1, 2019, the Company entered into an amended and restated
employment agreement with Ms. Stach in connection with her new
role as Executive Vice President that became effective on
May 1, 2019. Other than related to Ms. Stach's change in
role, the compensation terms and other material terms of
Ms. Stach's employment with the Company remain
unchanged.
The base
salaries are subject to annual increases as the Compensation
Committee may approve in their discretion and other benefits
generally available to other employees and our other executive
officers, and each will be eligible for an annual bonus for each
calendar year during his or her respective employment based on a
combination of his or her respective continued employment with the
Company and the achievement of certain performance goals
established by our Board of Directors and our Compensation
Committee.
29
Table of
Contents
If employment
is terminated for any reason other than for cause,
change-in-control or death or disability, the named executive
officer is entitled to receive all accrued salary, bonus
compensation, if any, to the extent earned, whether or not vested
without regard to such termination (other than defined contribution
plan or profit sharing plan benefits which will be paid in
accordance with the applicable plan), any benefits under any plans
of the Company in which the named executive officer is a
participant to the full extent of the named executive officer's
rights under such plans, full vesting of all awards granted to the
named executive officer under the 2014 Incentive Plan, accrued
vacation pay and any appropriate business expenses incurred by the
named executive officer in connection with his or her duties
hereunder, all to the date of termination.
In addition,
the named executive officer will receive as severance compensation
his or her base salary (at the rate payable at the time of such
termination), for a period of 36 months, with respect to
Mr. Wallace, and 12 months, with respect to
Mr. Dupuy, Mr. Barnes and Ms. Stach, from the date
of such termination; provided, however, that if the named executive
officer is employed by a new employer during such period, the
severance compensation payable to the named executive officer
during such period will be reduced by the amount of compensation
that the named executive officer is receiving from the new
employer. However, the named executive officer is under no
obligation to mitigate the amount owed the named executive officer
by seeking other employment or otherwise.
In addition to
the severance payment, the named executive officer will be paid an
amount equal to the greater of: (i) two times the average
annual cash bonus, if any, earned by the named executive officer in
the two years immediately preceding the date of termination,
without regard to any elective income deferral or conversion of
such bonus into stock or any other non-cash consideration; and
(ii) two times the product of the named executive officer's
base salary and 0.67 with respect to Mr. Wallace, and 0.33
with respect to Mr. Dupuy, Mr. Barnes and Ms. Stach.
Each named executive officer will be entitled to accelerated
vesting of any accrued benefit under each deferred compensation
plan.
If a named
executive officer is terminated for disability, the terminated
named executive officer will receive the benefits described above,
all to the date of termination, with the exception of medical and
dental benefits, if any, which shall continue at the Company's
expense through the then current one-year term of the employment
agreement. If a named executive officer's employment terminates due
to death, the terminated named executive officer's estate will
receive the benefits described above.
The severance
payment in the event of a change in control will consist of:
(1) three times the terminated officer's annual base salary
(at the rate payable at the time of such termination), and
(2) an amount equal to the greater of: (i) two times the
average annual cash bonus, if any, earned by the terminated officer
in the two years immediately preceding the date of termination,
without regard to any elective income deferral or conversion of
such bonus into stock or any other non-cash consideration; and
(ii) two times the product of the terminated officer's base
salary and 0.67 with respect to Mr. Wallace, and 0.33 with
respect to Mr. Dupuy, Mr. Barnes and Ms. Stach. Such
severance compensation shall be paid in a lump sum promptly after
the date of such termination, and in no event later than two and a
half months after the end of the year in which such termination
occurs. If the payments due to the change-in-control result in an
excise tax to the terminated officer, under Section 4999 of
the Code, all change-in-control payments to the terminated officer
may be limited to an amount that is less than 300% of his or her
average annual compensation. This limit would not apply in the
event that the terminated officer's net after-tax benefits are
greater after considering the effect of the excise tax.
Each employment
agreement contains customary non-competition and non-solicitation
covenants that apply during the term and for 12 months
following a termination upon a change in control, so long as the
payments to which the terminated officer is entitled as a result of
his or her termination upon a change of control are made on a
timely basis.
30
Table of
Contents
COMPENSATION TABLES
Summary Compensation Table
The table below
sets forth the compensation paid in fiscal years 2019, 2018, and
2017 to our principal executive officer and the three most highly
compensated executive officers. The four executive officers are
referred to in this proxy statement as our named executive
officers.
Each of our
named executive officers has agreed to take 100% of his or her
salary, bonus and long-term incentive compensation in the form of
restricted common stock under our 2014 Incentive Plan since such
officers began their tenure with the Company. In compliance with
the terms of the Amended and Restated Alignment of Interest Program
described above, the election to acquire stock, otherwise payable
in cash, caused the named executive officers to be eligible to
receive additional stock awards based upon a multiple described on
page 21 of this proxy statement.
All shares of
restricted stock issued in lieu of cash compensation and any shares
of restricted stock issued under the Amended and Restated Alignment
of Interest Program are subject to a vesting schedule whereby no
shares vest until the third, fifth or eighth anniversary of the
date of grant, at which time 100% of the shares of restricted stock
will vest, subject to continued employment.
The following
table sets forth the compensation of our named executive officers
for the fiscal years 2019, 2018, and 2017.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Salary |
|
Bonus |
|
|
|
|
|
|
|
Name and Principal Position
|
|
Year |
|
Compensation
Paid in
Cash(1) |
|
Compensation
Paid in
Stock(2) |
|
Compensation
Paid in
Cash |
|
Compensation
Paid in
Stock(3) |
|
Stock
Awards(4) |
|
All Other
Compensation(5) |
|
Total(7) |
|
Timothy G. Wallace
|
|
|
2019 |
|
$ |
— |
|
$ |
540,000 |
|
$ |
— |
|
$ |
216,000 |
|
$ |
1,829,164 |
|
$ |
10,800 |
|
$ |
2,595,964 |
|
Chief Executive Officer and
|
|
|
2018 |
|
$ |
— |
|
$ |
458,167 |
|
$ |
— |
|
$ |
183,267 |
|
$ |
1,606,543 |
|
$ |
— |
|
$ |
2,247,977 |
|
President
|
|
|
2017 |
|
$ |
— |
|
$ |
376,333 |
|
$ |
— |
|
$ |
150,533 |
|
$ |
1,065,151 |
|
$ |
— |
|
$ |
1,592,017 |
|
David H. Dupuy(6)
|
|
|
2019 |
|
$ |
— |
|
$ |
233,333 |
|
$ |
— |
|
$ |
23,333 |
|
$ |
1,115,165 |
|
$ |
11,279 |
|
$ |
1,383,110 |
|
Executive Vice President and
|
|
|
2018 |
|
$ |
— |
|
$ |
— |
|
$ |
— |
|
$ |
— |
|
$ |
— |
|
$ |
— |
|
$ |
— |
|
Chief Financial Officer
|
|
|
2017 |
|
$ |
— |
|
$ |
— |
|
$ |
— |
|
$ |
— |
|
$ |
— |
|
$ |
— |
|
$ |
— |
|
W. Page Barnes
|
|
|
2019 |
|
$ |
— |
|
$ |
328,000 |
|
$ |
— |
|
$ |
131,200 |
|
$ |
1,111,109 |
|
$ |
8,930 |
|
$ |
1,579,239 |
|
Executive Vice President and
|
|
|
2018 |
|
$ |
— |
|
$ |
271,167 |
|
$ |
— |
|
$ |
108,467 |
|
$ |
950,883 |
|
$ |
— |
|
$ |
1,330,517 |
|
Chief Operating Officer
|
|
|
2017 |
|
$ |
— |
|
$ |
214,333 |
|
$ |
— |
|
$ |
85,723 |
|
$ |
606,640 |
|
$ |
— |
|
$ |
906,696 |
|
Leigh Ann Stach
|
|
|
2019 |
|
$ |
— |
|
$ |
266,000 |
|
$ |
— |
|
$ |
106,400 |
|
$ |
901,044 |
|
$ |
1,000 |
|
$ |
1,274,444 |
|
Executive Vice President and
|
|
|
2018 |
|
$ |
— |
|
$ |
220,500 |
|
$ |
— |
|
$ |
188,200 |
|
$ |
876,216 |
|
$ |
— |
|
$ |
1,284,916 |
|
Chief Accounting Officer
|
|
|
2017 |
|
$ |
— |
|
$ |
175,000 |
|
$ |
— |
|
$ |
70,000 |
|
$ |
495,272 |
|
$ |
— |
|
$ |
740,272 |
|
- (1)
- All of our named
executive officers agreed to acquire shares of restricted common
stock in lieu of any cash compensation for the fiscal years ended
December 31, 2019, 2018 and 2017, as applicable.
- (2)
- The amounts represent
the annual base salary of each named executive officer set forth in
the table pursuant to their employment agreements, 100% of which
was used to acquire shares of our restricted common stock in lieu
of cash. The number of shares of common stock issued in 2019 was
based on $29.78, which was the average price of our common stock
for the 10 days preceding January 14, 2019, the
determination date. The number of shares of common stock issued in
2018 was based on $26.99, which was the average price of our common
stock for the 10 days preceding January 16, 2018, the
determination date. The number of shares of common stock issued in
2017 was based on $23.05, which was the average price of our common
stock for the 10 days preceding January 13, 2017, the
determination date. All of the shares of our restricted common
stock issued in lieu of cash compensation are subject to an
eight-year cliff vesting schedule whereby no shares vest until the
eighth anniversary of the date of grant, at which time 100% of the
shares of restricted stock will vest, subject to continued
employment.
- (3)
- The bonus amounts
paid in each of the years 2019, 2018 and 2017 represent the annual
bonus of each named executive officer set forth in the table
pursuant to their employment agreements, 100% of which was used to
acquire shares of our restricted common stock in lieu of cash. The
number of shares of common stock issued in 2019 was based on
$42.50, which was the average price of our common stock for the
10 days preceding August 15, 2019, the determination
date. The number of shares of common stock issued in 2018 was based
on $31.26, which was the average price of our common stock for the
10 days preceding August 15, 2018, the determination
date. The number of shares of common stock issued in 2017 was based
on $25.18, which was the average price of our common stock for the
10 days preceding August 28, 2017, the determination
date. All of the shares of our restricted common stock issued in
lieu of cash compensation are subject to an eight-year cliff
vesting schedule whereby no shares vest until the eighth
anniversary of the date of grant, at which time 100% of the shares
of restricted stock will vest, subject to continued employment.
- (4)
- Represents the
aggregate fair value computed in accordance with FASB ASC Topic 718
of awards of restricted common stock to the named executive
officers for the years ended December 31, 2019, 2018, and 2017
under the 2014 Incentive Plan, as amended. The dollar values of the
awards related to base salaries and bonuses for 2019, 2018, and
2017 are based on the grant date value of such awards and the
restriction multiples for cash compensation deferrals outlined in
our Amended and Restated Alignment of Interest Program. Awards
granted to our
31
Table of
Contents
named executive
officers' in connection with their base salaries for 2019, 2018,
and 2017, were based on grant date values of such awards of $30.67
per share, $25.95 per share, and $22.67 per share, respectively.
Awards granted to our named executive officers' in connection with
their bonuses for 2019, 2018 and 2017, were based on grant date
values of such awards of $42.90, $31.73 per share and $25.96 per
share, respectively. The dollar values of the awards related to the
Company's total stockholder return performance, relative to its
peer group, for the years ended December 31, 2019, 2018 and
2017, as outlined in the Executive Officer Incentive Program, are
based on the grant date value of such awards of $42.90 per share,
$31.73 per share and $24.88 per share, respectively. The restricted
share award of 5,000 shares of common stock granted to
Mr. Dupuy upon becoming a named executive officer in 2019 was
based on a grant date value of $36.29 per share.
- (5)
- Includes employer
contributions to the executive officer's health savings account
(HSA) and 401(k), as well as moving and relocation expenses for
Mr. Dupuy.
- (6)
- Joined the Company as
a named executive officer on May 1, 2019 and was awarded 5,000
shares of restricted stock.
- (7)
- A significant portion
of the named executive officer's compensation is performance based,
as set forth in the following table:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Performance Based Incentive Compensation |
|
Name
|
|
Year |
|
Total
Compensation |
|
Bonus
Stock(1) |
|
Alignment
of
Interest
Stock(2) |
|
1 Year
Total
Shareholder
Return
Stock |
|
3 Year
Total
Shareholder
Return
Stock |
|
Total
Performance
Based
Incentive
Compensation |
|
Percent of
Total
Compensation |
|
Timothy G. Wallace
|
|
2019 |
|
$ |
2,595,964 |
|
$ |
216,000 |
|
$ |
884,164 |
|
$ |
405,000 |
|
$ |
540,000 |
|
$ |
2,045,164 |
|
|
78.8 |
% |
|
|
2018 |
|
$ |
2,247,977 |
|
$ |
183,267 |
|
$ |
690,209 |
|
$ |
458,167 |
|
$ |
458,167 |
|
$ |
1,789,810 |
|
|
79.6 |
% |
|
|
2017 |
|
$ |
1,592,017 |
|
$ |
150,533 |
|
$ |
500,651 |
|
$ |
282,250 |
|
$ |
282,250 |
|
$ |
1,215,684 |
|
|
76.4 |
% |
David H. Dupuy(3)
|
|
2019
|
|
$ |
1,383,110 |
|
$ |
23,333 |
|
$ |
321,215 |
|
$ |
262,500 |
|
$ |
350,000 |
|
$ |
957,048 |
|
|
69.2 |
% |
|
|
2018 |
|
$ |
— |
|
$ |
— |
|
$ |
— |
|
$ |
— |
|
$ |
— |
|
$ |
— |
|
|
— |
|
|
|
2017 |
|
$ |
— |
|
$ |
— |
|
$ |
— |
|
$ |
— |
|
$ |
— |
|
$ |
— |
|
|
— |
|
W. Page Barnes
|
|
2019
|
|
$ |
1,579,239 |
|
$ |
131,200 |
|
$ |
537,109 |
|
$ |
246,000 |
|
$ |
328,000 |
|
$ |
1,242,309 |
|
|
78.7 |
% |
|
|
2018 |
|
$ |
1,330,517 |
|
$ |
108,467 |
|
$ |
408,549 |
|
$ |
271,167 |
|
$ |
271,167 |
|
$ |
1,059,350 |
|
|
79.6 |
% |
|
|
2017 |
|
$ |
906,696 |
|
$ |
85,723 |
|
$ |
285,140 |
|
$ |
160,750 |
|
$ |
160,750 |
|
$ |
692,363 |
|
|
76.4 |
% |
Leigh Ann Stach
|
|
2019
|
|
$ |
1,274,444 |
|
$ |
106,400 |
|
$ |
435,544 |
|
$ |
199,500 |
|
$ |
266,000 |
|
$ |
1,007,444 |
|
|
79.0 |
% |
|
|
2018 |
|
$ |
1,284,916 |
|
$ |
188,200 |
|
$ |
435,216 |
|
$ |
220,500 |
|
$ |
220,500 |
|
$ |
1,064,416 |
|
|
82.8 |
% |
|
|
2017 |
|
$ |
740,272 |
|
$ |
70,000 |
|
$ |
232,772 |
|
$ |
131,250 |
|
$ |
131,250 |
|
$ |
565,272 |
|
|
76.4 |
% |
- (1)
- Each executive
officer has elected to take 100% of their salary and cash bonus in
deferred stock with an 8-year cliff vesting.
- (2)
- Alignment of interest
stock grants per the Amended and Restated Alignment of Interest
Program which is part of the Company's Incentive Plan.
- (3)
- Mr. Dupuy joined
the Company on May 1, 2019.
32
Table of
Contents
Grants of Plan-Based Awards
The following
table provides additional information relating to grants of
plan-based awards made to our named executive officers during
2019.
|
|
|
|
|
|
|
|
|
|
|
Name
|
|
Grant date |
|
All other
stock awards:
Number of
shares of
stock (#)(1) |
|
Grant date
fair value
of share
awards (#) |
|
Timothy G. Wallace
|
|
|
1/15/2019 |
|
|
18,133 |
|
$ |
556,139 |
|
|
|
|
8/15/2019 |
|
|
29,251 |
|
$ |
1,254,868 |
|
David H. Dupuy
|
|
|
5/1/2019 |
|
|
5,000 |
|
$ |
181,450 |
|
|
|
|
5/15/2019 |
|
|
6,359 |
|
$ |
235,665 |
|
|
|
|
8/15/2019 |
|
|
16,213 |
|
$ |
695,538 |
|
W. Page Barnes
|
|
|
1/15/2019 |
|
|
11,015 |
|
$ |
337,830 |
|
|
|
|
8/15/2019 |
|
|
17,768 |
|
$ |
762,247 |
|
Leigh Ann Stach
|
|
|
1/15/2019 |
|
|
8,933 |
|
$ |
273,975 |
|
|
|
|
8/15/2019 |
|
|
14,408 |
|
$ |
618,103 |
|
- (1)
- The table below shows
the number of restricted shares of common stock awarded to the
named executive officers in 2019 pursuant to the 2014 Incentive
Plan.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Incentive Awards |
|
|
|
|
|
Name
|
|
Company
Match
Salary(#) |
|
Company
Match
Bonus(#) |
|
1 Year
Total
Shareholder
Return
Stock(#) |
|
3 Year
Total
Shareholder
Return
Stock(#) |
|
CFO
Grant(#) |
|
Total
Stock
Awards(#) |
|
Timothy G. Wallace
|
|
|
18,133 |
|
|
5,082 |
|
|
10,358 |
|
|
13,811 |
|
|
— |
|
|
47,384 |
|
David H. Dupuy
|
|
|
6,359 |
|
|
549 |
|
|
6,713 |
|
|
8,951 |
|
|
5,000 |
|
|
27,572 |
|
W. Page Barnes
|
|
|
11,015 |
|
|
3,087 |
|
|
6,292 |
|
|
8,389 |
|
|
— |
|
|
28,783 |
|
Leigh Ann Stach
|
|
|
8,933 |
|
|
2,503 |
|
|
5,102 |
|
|
6,803 |
|
|
— |
|
|
23,341 |
|
Outstanding Equity Awards at December 31, 2019
The following
table sets forth all outstanding equity awards held by each of our
named executive officers at December 31, 2019.
|
|
|
|
|
|
|
|
Name
|
|
Number of Shares
or Units of
Stock That Have
Not Vested (#) |
|
Market Value of
Shares or Units
of Stock That
Have Not
Vested ($)(1) |
|
Timothy G. Wallace
|
|
|
184,832 |
(2) |
$ |
7,921,900 |
|
David H. Dupuy
|
|
|
27,572 |
(2) |
$ |
1,181,736 |
|
W. Page Barnes
|
|
|
105,549 |
(2) |
$ |
4,523,830 |
|
Leigh Ann Stach
|
|
|
90,519 |
(2) |
$ |
3,879,644 |
|
- (1)
- The market value of
unvested restricted common stock is calculated by multiplying the
number of unvested shares of restricted common stock held by the
applicable named executive officer by the closing price of our
common stock on December 31, 2019, which was $42.86.
- (2)
- These shares of
restricted common stock are subject to eight-year cliff vesting
through 2027, subject to continued employment with the Company on
the vesting date.
33
Table of
Contents
Post-Employment Compensation
The tables
below illustrate the compensation that would have been received by
each of the named executive officers assuming the officer had been
terminated or had been eligible to retire and had elected to retire
on December 31, 2019, and that any additional conditions to
vesting of restricted stock awards under restricted stock award
agreements had been met.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Timothy G. Wallace
Chief Executive Officer and President
|
|
Voluntary
Termination |
|
Not for
Cause
Termination |
|
Change-in-
Control |
|
Death or
Disability |
|
Retirement |
|
Cash Severance Benefit(1)
|
|
$ |
— |
|
$ |
2,343,600 |
|
$ |
2,343,600 |
|
$ |
— |
|
$ |
— |
|
Accelerated Vesting Of Restricted
Stock(3)
|
|
$ |
— |
|
$ |
12,531,278 |
|
$ |
12,531,278 |
|
$ |
12,531,278 |
|
$ |
12,531,278 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Value of Payments
|
|
$ |
— |
|
$ |
14,874,878 |
|
$ |
14,874,878 |
|
$ |
12,531,278 |
|
$ |
12,531,278 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
David H. Dupuy
Executive Vice President and Chief
Financial Officer
|
|
Voluntary
Termination |
|
Not for
Cause
Termination |
|
Change-in-
Control |
|
Death or
Disability |
|
Retirement |
|
Cash Severance Benefit(2)
|
|
$ |
— |
|
$ |
581,000 |
|
$ |
1,281,000 |
|
$ |
— |
|
$ |
— |
|
Accelerated Vesting Of Restricted
Stock(3)
|
|
$ |
— |
|
$ |
1,477,770 |
|
$ |
1,477,770 |
|
$ |
1,477,770 |
|
$ |
1,477,770 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Value of Payments
|
|
$ |
— |
|
$ |
2,058,770 |
|
$ |
2,758,770 |
|
$ |
1,477,770 |
|
$ |
1,477,770 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
W. Page Barnes
Executive Vice President and Chief
Operating Officer
|
|
Voluntary
Termination |
|
Not for
Cause
Termination |
|
Change-in-
Control |
|
Death or
Disability |
|
Retirement |
|
Cash Severance Benefit(2)
|
|
$ |
— |
|
$ |
567,667 |
|
$ |
1,223,667 |
|
$ |
— |
|
$ |
— |
|
Accelerated Vesting Of Restricted
Stock(3)
|
|
$ |
— |
|
$ |
7,091,744 |
|
$ |
7,091,744 |
|
$ |
7,091,744 |
|
$ |
7,091,744 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Value of Payments
|
|
$ |
— |
|
$ |
7,659,411 |
|
$ |
8,315,411 |
|
$ |
7,091,744 |
|
$ |
7,091,744 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Leigh Ann Stach
Executive Vice President and Chief
Accounting Officer
|
|
Voluntary
Termination |
|
Not for
Cause
Termination |
|
Change-in-
Control |
|
Death or
Disability |
|
Retirement |
|
Cash Severance Benefit(2)
|
|
$ |
— |
|
$ |
560,600 |
|
$ |
1,092,600 |
|
$ |
— |
|
$ |
— |
|
Accelerated Vesting Of Restricted
Stock(3)
|
|
$ |
— |
|
$ |
6,168,454 |
|
$ |
6,168,454 |
|
$ |
6,168,454 |
|
$ |
6,168,454 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Value of Payments
|
|
$ |
— |
|
$ |
6,729,054 |
|
$ |
7,261,054 |
|
$ |
6,168,454 |
|
$ |
6,168,454 |
|
- (1)
- Represents the annual
base salary at December 31, 2019 for a period of 36-months
from the date of such termination, payable in monthly
installments.
- (2)
- Represents the annual
base salary at December 31, 2019 for a period of 12-months
from the date of such termination, payable in monthly
installments.
- (3)
- Based upon the
closing price of a share of the Company's Common Stock on the New
York Stock Exchange on December 31, 2019 of
$42.86.
34
Table of
Contents
EQUITY COMPENSATION PLAN
INFORMATION
The following
table gives information about shares of our common stock that may
be issued under our 2014 Incentive Plan as of December 31,
2019.
|
|
|
|
|
|
|
|
|
|
|
Plan Category
|
|
Number of Securities
to be Issued Upon
Exercise of
Outstanding Options,
Warrants and Rights |
|
Weighted Average
Exercise Price of
Outstanding
Options,
Warrants and
Rights |
|
Number of Securities
Remaining Available for
Future Issuance Under
Equity Compensation Plans
(Excluding Securities
Reflected in First Column) |
|
Equity compensation plans approved by
stockholders(1)
|
|
|
— |
|
|
— |
|
|
579,205 |
|
Equity compensation plans not approved by
stockholders
|
|
|
— |
|
|
— |
|
|
277,262 |
(2) |
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
— |
|
|
— |
|
|
856,467 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- (1)
- Our 2014 Incentive
Plan automatically increases, on an annual basis, the number of
shares of common stock available for issuance under the 2014
Incentive Plan to an amount equal to 7% of the total number of
shares of common stock outstanding on December 31 of the
immediately preceding year. These annual increases are required
because of the level of restricted stock, versus cash, we utilize
in our compensation methodology and was approved by a vote of our
shareholders in 2017.
- (2)
- These 277,262 shares
are reserved under our 2014 Incentive Plan for purchase by our
employees and directors in exchange for the cash compensation. See
"2014 Incentive Plan" beginning on page 20.
35
Table of
Contents
PROPOSAL 2
NON-BINDING ADVISORY VOTE ON EXECUTIVE COMPENSATION
The Dodd-Frank
Wall Street Reform and Consumer Protection Act of 2010, or the
Dodd-Frank Act, enables the Company's stockholders to vote to
approve, on a non-binding advisory basis, the compensation of the
Company's named executive officers as disclosed in this proxy
statement in accordance with the SEC's rules.
As discussed in
the Compensation Discussion and Analysis section of this proxy
statement beginning on page 16, the Company's executive
compensation policies are designed to align the interests of the
named executive officers with the interests of our shareholders,
link executive compensation to the Company's overall performance,
and attract, retain, and motivate our named executive officers. The
Board believes that its executive compensation programs have been
effective at appropriately aligning pay and Company performance,
promoting the achievement of the long-term positive results in its
performance criteria, and enabling the Company to attract and
retain talented executives within its industry.
The Board is
asking stockholders to indicate their support for the named
executive officer compensation described in this proxy statement.
This proposal, commonly known as a "say-on-pay" proposal, gives
stockholders the opportunity to express views on the Company's
executive compensation for its named executive officers. This vote
is not intended to address any specific item of compensation, but
rather the overall compensation of the Company's named executive
officers and the policies and procedures described in this proxy
statement. Accordingly, the Board asks stockholders to vote "FOR"
the following resolution:
RESOLVED, that the stockholders of
Community Healthcare Trust Incorporated approve, on a non-binding
advisory basis, the compensation of the named executive officers as
disclosed pursuant to Item 402 of Regulation S-K in the
Company's proxy statement for the 2020 annual meeting of
stockholders.
Although this
is an advisory vote that will not be binding on the Compensation
Committee or the Board, the Board will carefully review the results
of the vote. The Compensation Committee will also carefully
consider stockholders' concerns when designing future executive
compensation programs.
Required Vote
The affirmative
vote of a majority of the shares represented at the meeting and
entitled to vote is required to approve, on an advisory basis, the
say on pay vote. As an advisory vote, this proposal is not binding
upon us. However, the Compensation Committee of our Board of
Directors, which is responsible for designing and administering our
executive compensation program, values the opinions expressed by
our stockholders and will consider the outcome of the vote when
making future compensation decisions.
Our
Board of Directors unanimously recommends a vote "FOR" the
resolution approving the compensation of the Company's named
executive officers
36
Table of
Contents
PROPOSAL 3
NON-BINDING ADVISORY VOTE ON THE FREQUENCY OF THE VOTE ON EXECUTIVE
COMPENSATION
The Dodd-Frank
Act requires the Company to include, at least once every six years,
an advisory vote regarding the frequency of the non-binding
advisory vote on executive compensation. In casting their advisory
vote, stockholders may choose among four options: (1) an
annual vote, (2) a vote every two years (biennial), (3) a
vote every three years (triennial) or (4) to abstain from
voting. The Board believes that an annual voting is most
appropriate for the Company because it believes that it has become
standard within its industry and that an annual vote affords the
stockholders greater opportunity to provide feedback to the
management team of the Company and the Board. Like the advisory
vote on executive compensation, the advisory vote on the frequency
of such vote is non-binding on the Compensation Committee of the
Board. Although the vote is non-binding, the Company's Board and
the Compensation Committee will review the voting results and will
respect the expressed desire of the Company's stockholders by
implementing the option, if any, that receives a majority of votes
cast. Abstentions and broker non-votes will have no effect on the
outcome of this advisory vote. A majority vote requires that one
option receive more votes than the other two options taken
together. If no option receives the majority of votes cast, the
Board will select the annual option to be in effect until the next
vote on the frequency of the vote on executive
compensation.
Required Vote
The affirmative
vote of a majority of the shares represented at the meeting and
entitled to vote is required to approve, on an advisory basis, the
frequency of future stockholder say on pay votes. As an advisory
vote, this proposal is not binding upon us. Our Board of Directors
will consider the outcome of the vote when determining the
frequency of holding future stockholder say on pay
votes.
Our
Board of Directors unanimously recommends a vote for an "ANNUAL"
vote on executive compensation
37
Table of
Contents
PROPOSAL 4
RATIFICATION OF THE APPOINTMENT OF BDO USA, LLP AS OUR
INDEPENDENT
REGISTERED PUBLIC ACCOUNTANTS FOR 2020
General
We are asking
our stockholders to ratify the selection of BDO USA, LLP as
our independent registered public accountants for 2020. Although
current law, rules and regulations, as well as the charter of the
Audit Committee, require the Audit Committee to engage, retain and
supervise our independent registered public accountants, we view
the selection of the independent registered public accountants as
an important matter of stockholder concern and thus are submitting
the selection of BDO USA, LLP for ratification by stockholders
as a matter of good corporate practice.
The Audit
Committee appointed BDO USA, LLP to serve as our independent
registered public accountants for the 2019 fiscal year and has
appointed BDO USA, LLP to serve as our independent registered
public accountants for the 2020 fiscal year. A representative of
BDO USA, LLP is expected to attend the annual meeting. If
present, the representative will have the opportunity to make a
statement and will be available to respond to appropriate
questions. BDO USA, LLP has served as our independent
registered public accountants since 2015.
Audit and Non-Audit Services
Fees related to
services performed for us by BDO USA, LLP in fiscal years 2019
and 2018 are as follows:
|
|
|
|
|
|
|
|
|
|
2019 |
|
2018 |
|
Audit Fees(1)
|
|
$ |
726,430 |
|
$ |
484,921 |
|
Audit-Related Fees(2)
|
|
|
19,066 |
|
|
— |
|
Tax Fees
|
|
|
— |
|
|
— |
|
All Other Fees
|
|
|
— |
|
|
— |
|
|
|
|
|
|
|
|
|
Total
|
|
$ |
745,496 |
|
$ |
484,921 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- (1)
- Audit fees include
fees and expenses associated with the audit of our financial
statements, the reviews of the financial statements in our
quarterly reports on Form 10-Q, and services provided in
connection with registration statements and periodic reports filed
with the Securities and Exchange Commission. Audit fees for 2019
include fees associated with registration statements totaling
$109,492 and fees related to auditing our internal control over
financial reporting. Audit fees for 2018 include fees associated
with registration statements totaling $74,162.
- (2)
- Audit-related fees
for 2019 included fees associated with Rule 3-14
audits.
In accordance
with the procedures set forth in its charter, the Audit Committee
pre-approves all auditing services and permitted non-audit and tax
services (including the fees and terms of those services) to be
performed for us by our independent registered public accountants
prior to their engagement with respect to such services, subject to
the de minimis exceptions for non-audit services permitted by the
Exchange Act, which are approved by the Audit Committee prior to
the completion of the audit.
Required Vote
The affirmative
vote by a majority of the votes cast at the annual meeting is
required for the ratification of the appointment of BDO
USA, LLP as our independent registered public
accountants.
38
Table of
Contents
Abstentions will have
no effect on this proposal. If our stockholders fail to ratify this
appointment, the Audit Committee will reconsider whether to retain
BDO USA, LLP and may retain that firm or another firm without
resubmitting the matter to our stockholders. Even if the
appointment is ratified, the Audit Committee may, in its
discretion, direct the appointment of a different independent
registered public accountant at any time during the year if it
determines that such change would be in our best interests and in
the best interests of our stockholders.
Our
Board of Directors unanimously recommends a vote "FOR" the
ratification of BDO USA, LLP as our independent registered
public accountants for 2020.
39
Table of
Contents
REPORT OF THE AUDIT COMMITTEE
The
information provided in this section shall not be deemed to be
"soliciting material" or to be "filed" with the SEC or subject to
its proxy regulations or to the liabilities of Section 18 of
the Exchange Act. The information provided in this section shall
not be deemed to be incorporated by reference into any filing under
the Securities Act of 1933, as amended, or the Exchange
Act.
The Audit
Committee oversees our financial reporting process on behalf of the
Board of Directors. Management has the primary responsibility for
the preparation, consistency and fair presentation of the financial
statements, the accounting and financial reporting process, the
systems of internal control, and the procedures designed to ensure
compliance with accounting standards, applicable laws and
regulations. Management is also responsible for its assessment of
the design and effectiveness of our internal control over financial
reporting. Our independent registered public accountants are
responsible for performing an audit in accordance with the
standards of the Public Company Accounting Oversight Board (United
States), or PCAOB, and expressing an opinion on the conformity of
the financial statements of the Company with U.S. generally
accepted accounting principles and expressing an opinion on the
effectiveness of our internal controls over financial reporting.
The internal auditors are responsible to the Audit Committee and
the Board of Directors for testing the integrity of the financial
accounting and reporting control systems and such other matters as
the Audit Committee and the Board of Directors
determine.
In fulfilling
its oversight responsibilities, the Audit Committee reviewed and
discussed with management the audited financial statements of the
Company for the year ended December 31, 2019 and management's
assessment of the design and effectiveness of our internal control
over financial reporting as of December 31, 2019. The
discussion addressed the quality, and not just the acceptability,
of the accounting principles, the reasonableness of significant
judgments and the clarity of disclosures in the financial
statements.
The Audit
Committee reviewed and discussed with the independent public
accountants their judgments as to the quality of our accounting
principles and such other matters as are required to be discussed
with the committee under PCAOB auditing standards including,
without limitation, the matters required to be discussed by PCAOB
Auditing Standard No. 1301. In addition, the Audit Committee
received the written disclosures and the letter from the
independent registered public accountants required by applicable
requirements of the PCAOB regarding the independent registered
public accountants' communications with the Audit Committee
concerning independence, discussed with the independent registered
public accountants their independence from management and the
Company, and considered the compatibility of non-audit services
with the auditors' independence.
The Audit
Committee discussed with our internal and independent registered
public accountants the overall scope and plans for their respective
audits. The Audit Committee met with the internal and independent
registered public accountants, with and without management present,
to discuss the results of their examinations, their understanding
of our internal controls, and the overall quality of our financial
reporting.
In reliance
upon the reviews and discussions referred to above, the Audit
Committee recommended to the Board of Directors (and the Board has
approved) that the audited financial statements be included in our
annual report to stockholders for filing with the SEC.
The members of
the Audit Committee are not professionally engaged in the practice
of auditing or accounting and are not experts in the fields of
accounting or auditing, including with respect to auditor
independence. Members of the Audit Committee rely without
independent verification on the information provided to them and on
the representations made by management and the independent
registered public accounting firm. Accordingly, the Audit
Committee's oversight does not provide an independent basis to
determine that management has maintained appropriate accounting and
financial
40
Table of
Contents
reporting principles,
or appropriate internal controls and procedures designed to assure
compliance with accounting standards and applicable laws and
regulations. Furthermore, the Audit Committee's considerations and
discussions referred to above do not assure that the audit of the
Company's financial statements has been carried out in accordance
with the standards of the PCAOB, that the financial statements are
presented in accordance with generally accepted accounting
principles or that BDO USA, LLP is in fact
"independent."
Audit Committee:
Robert Hensley (Chairman)
Alan Gardner
Claire Gulmi
41
Table of
Contents
BENEFICIAL OWNERSHIP OF SHARES OF COMMON
STOCK
Directors, Executive Officers and Other Stockholders
As of
March 6, 2020, we had 31 stockholders of record. Except as
otherwise stated in a footnote, the following table presents
certain information regarding the beneficial ownership of our
common stock as of March 6, 2020 by: (i) the persons
known by us to own beneficially more than 5% of our common stock;
(ii) each of our directors, nominees for director and named
executive officers; and (iii) all of our directors, nominees
for director, and executive officers as a group. Each person named
in the table has sole voting and investment power with respect to
all of the common stock shown as beneficially owned by such person,
except as otherwise set forth in the notes to the table.
The SEC has
defined "beneficial ownership" of a security to mean the
possession, directly or indirectly, of voting power and/or
investment power over such security. A stockholder is also deemed
to be, as of any date, the beneficial owner of all securities that
such stockholder has the right to acquire within 60 days after
that date through (1) the exercise of any option, warrant or
right, (2) the conversion of a security, (3) the power to
revoke a trust, discretionary account or similar arrangement or
(4) the automatic termination of a trust, discretionary
account or similar arrangement. In computing the number of shares
beneficially owned by a person and the percentage ownership of that
person, our common stock subject to options or other rights (as set
forth above) held by that person that are currently exercisable or
will become exercisable within 60 days thereafter, are deemed
outstanding, while such shares are not deemed outstanding for
purposes of computing percentage ownership of any other
person.
Unless
otherwise indicated, the business address of all the individuals
and entities is c/o Community Healthcare Trust Incorporated,
3326 Aspen Grove Drive, Suite 150, Franklin,
Tennessee 37067. No common stock beneficially owned by any
director or named executive officer has been pledged as security
for a loan.
|
|
|
|
|
|
|
|
Name of Beneficial Owner
|
|
Number of Shares
Beneficially
Owned (#) |
|
Percentage of
All Shares
(%)(1) |
|
5% Stockholders
|
|
|
|
|
|
|
|
BlackRock, Inc.
|
|
|
3,215,961 |
(2) |
|
14.7 |
% |
The Vanguard Group, Inc.
|
|
|
2,173,776 |
(3) |
|
9.9 |
% |
The Bank of New York Mellon
Corporation.
|
|
|
1,241,241 |
(4) |
|
5.7 |
% |
Cardinal Capital Management, LLC
|
|
|
1,198,032 |
(5) |
|
5.5 |
% |
Directors
|
|
|
|
|
|
|
|
Alan Gardner
|
|
|
30,446 |
|
|
* |
|
Claire Gulmi
|
|
|
7,037 |
|
|
* |
|
Robert Hensley
|
|
|
35,372 |
|
|
* |
|
Lawrence Van Horn
|
|
|
19,439 |
|
|
* |
|
Named Executive Officers
|
|
|
|
|
|
|
|
Timothy G. Wallace
|
|
|
760,756 |
|
|
3.5 |
% |
David H. Dupuy
|
|
|
52,653 |
|
|
* |
|
W. Page Barnes
|
|
|
207,635 |
|
|
* |
|
Leigh Ann Stach
|
|
|
159,072 |
|
|
* |
|
All Directors and Executive Officers as a Group
(8 persons total)
|
|
|
1,272,410 |
|
|
5.8 |
% |
- *
- Less than 1% of the
outstanding shares of common stock.
- (1)
- Based on 21,906,352
shares of common stock outstanding on March 6,
2020.
42
Table of
Contents
- (2)
- Based on a
Schedule 13G/A filed with the SEC on February 4, 2020,
BlackRock, Inc. has sole voting power with respect to
3,166,327 shares of common stock and sole dispositive power with
respect to 3,215,961 shares of common stock. A subsidiary of
BlackRock, Inc., BlackRock Fund Advisors, beneficially owns 5%
or greater of the outstanding shares of common stock reported on
BlackRock's Schedule 13G/A. BlackRock, Inc. is located at
55 East 52nd Street, New York, New York
10055.
- (3)
- Based on a
Schedule 13G/A filed with the SEC on February 12, 2020,
The Vanguard Group, Inc. has sole voting power with respect to
30,780 shares of common stock, shared voting power with respect to
2,100 shares of common stock, sole dispositive power with respect
to 2,142,801 shares of common stock and shared dispositive power
with respect to 30,975 shares of common stock. As reported on The
Vanguard Group Inc.'s Schedule 13G/A, Vanguard Fiduciary
Trust Company, a wholly-owned subsidiary of The Vanguard
Group, Inc., is the beneficial owner of 28,875 shares of
common stock, and Vanguard Investments Australia, Ltd., a
wholly-owned subsidiary of The Vanguard Group, Inc., is the
beneficial owner of 4,005 shares common stock outstanding of the
Company. The VanGuard Group, Inc. is located at 100 Vanguard
Boulevard, Malvern, PA 19355.
- (4)
- Based on a
Schedule 13G filed with the SEC on February 5, 2020, The
Bank of New York Mellon Corporation has sole voting power with
respect to 1,227,122 shares of common stock, sole dispositive power
with respect to 1,240,108 shares of common stock, and shared
dispositive power with respect to 60 shares of common stock. As
reported on The Bank of New York Mellon Corporation's
Schedule 13G, BNY Mellon IHC, LLC has sole voting power
with respect to 1,170,352 shares of common stock and sole
dispositive power with respect to 1,184,411 shares of common stock.
MBC Investments Corporation has sole voting power with respect to
1,170,352 shares of common stock and sole dispositive power with
respect to 1,184,411 shares of common stock. Mellon Investments
Corporation has sole voting power with respect to 1,109,009 shares
of common stock and sole dispositive power with respect to
1,109,009 shares of common stock. The Bank of New York Mellon
Corporation, BNY Mellon IHC, LLC, MBC Investments Corporation,
and Mellon Investments Corporation are located at 240 Greenwich
Street, New York, New York 10286.
- (5)
- Based on a
Schedule 13G/A filed with the SEC on February 14, 2020,
Cardinal Capital Management, LLC has sole voting power with
respect to 945,464 shares of common stock and sole dispositive
power with respect to 1,198,032 shares of common stock. Cardinal
Capital Management, LLC is located at Four Greenwich Office
Park, Greenwich, Connecticut 06831.
43
Table of
Contents
CERTAIN RELATIONSHIPS AND RELATED PARTY
TRANSACTIONS
Policies and Procedures for Related Person
Transactions
Our Audit
Committee has adopted a written policy governing the approval of
related party transactions that complies with all applicable
requirements of the SEC and the NYSE concerning related party
transactions. Under our policy, a related party transaction is a
transaction between the Company and a related party (including any
transaction requiring disclosure under Item 404 of
Regulation S-K under the Exchange Act), other than
transactions available to all employees generally or involving less
than $5,000 when aggregated with similar transactions. "Related
parties" include (i) an officer or director of the Company,
(ii) a person who is an immediate family member of an officer
or director; (iii) an entity which is owned or controlled by
an officer or director or an immediate family member of an officer
or director, or an entity in which an officer or director or an
immediate family member of an officer or director is deemed to have
a substantial ownership interest or control of such entity by
virtue of such person owning more than 20% of such entity; and
(iv) any person known to be the beneficial owner of more than
5% of any class of the Company's voting securities. Members of an
officer's or director's immediate family include such officer's or
director's spouse, child, stepchild, parent, stepparent, sibling,
mother-in-law, father-in-law, son-in-law, daughter-in-law,
brother-in-law or sister-in-law and any other person sharing the
household of such officer or director. For purposes of this policy,
officers are defined as "executive officers" under applicable
guidelines of the SEC. Additionally, a "Related Party" may be a
person or entity that proposes to enter into a transaction with the
Company if the Audit Committee finds that such transaction would
require disclosure under Item 404 of
Regulation S-K.
Our related
party transaction policy is administered by our Audit Committee. At
each fiscal year's first regularly-scheduled Audit Committee
meeting, management or the Corporate Governance Committee, as
applicable, will provide the Audit Committee with detailed
information concerning all related party transactions, if any, then
known by management to be entered into or to be continued by the
Company for the fiscal year. Under the related party transactions
policy, there is a general presumption that a related party
transaction with the Company will not be approved by the Audit
Committee. However, the Audit Committee may approve a related party
transaction if: (i) the Audit Committee finds that the
transaction is on terms comparable to those that could be obtained
in arm's length dealings with an unrelated third party; and
(ii) the Audit Committee finds that it has been fully apprised
of all significant conflicts that may exist or otherwise arise on
account of the transaction, and it believes, nonetheless, that the
Company is warranted entering into the related party transaction
and has developed an appropriate plan to manage the potential
conflicts of interest. The Audit Committee will consider each
proposed related party transaction and may approve the Company's
entering into or continuing such related party transaction if the
transaction satisfies the guidelines set forth above.
Related Party Transactions
Pursuant to its
authority and based on discussions with management and BDO
USA, LLP, the Audit Committee has determined that there have
been no related party transactions requiring disclosure under
Item 404(a) of Regulation S-K.
Legal Proceedings
We are not
aware of any current legal proceedings involving any of our
directors, director nominees, or executive officers and either the
Company or any of its subsidiaries.
44
Table of
Contents
STOCKHOLDER PROPOSALS FOR THE 2021 ANNUAL
MEETING
At the annual
meeting each year, the Board of Directors submits to stockholders
its nominees for election as directors. In addition, the Board may
submit other matters to the stockholders for action at the annual
meeting. Stockholders may also submit proposals for action at the
annual meeting.
Stockholders
interested in submitting a proposal for inclusion in our proxy
materials for the 2021 annual meeting of stockholders may do so by
following the procedures described in Rule 14a-8 of the
Exchange Act. If the 2021 annual meeting is held within
30 days of May 7, 2020, stockholder proposals must be
received by Timothy Wallace at 3326 Aspen Grove Drive,
Suite 150, Franklin, Tennessee, 37067, no later than
5:00 p.m., Eastern Time on November 20, 2020 in order for
such proposals to be considered for inclusion in the proxy
statement and form of proxy relating to such annual
meeting.
Any stockholder
proposals (including recommendations of nominees for election to
the Board of Directors) intended to be presented at the Company's
2021 annual meeting of stockholders, other than a stockholder
proposal submitted pursuant to Exchange Act Rule 14a-8, must
be received in writing at our principal executive offices no
earlier than on October 21, 2020, nor later than
5:00 p.m., Eastern Time, on November 20, 2020, together
with all supporting documentation required by our Bylaws. For more
complete information on these requirements, please refer to our
Bylaws.
OTHER MATTERS
As of the date
of this proxy statement, management does not know of any other
matters to be brought before the annual meeting other than those
set forth herein. However, if any other matters are properly
brought before the annual meeting, the persons named in the
enclosed form of proxy will have discretionary authority to vote
all proxies with respect to such matters in accordance with their
best judgment.
REGARDLESS
OF THE NUMBER OF SHARES YOU OWN, YOUR VOTE IS IMPORTANT TO THE
COMPANY. PLEASE SUBMIT A PROXY BY INTERNET OR, IF YOU REQUEST
WRITTEN PROXY MATERIALS BY RETURNING A COMPLETED, SIGNED AND DATED
PROXY CARD OR VOTING INSTRUCTION FORM.
AVAILABILITY OF ANNUAL REPORT ON FORM 10-K
Upon written
request of any record holder or beneficial owner of shares entitled
to vote at the annual meeting, we will provide, without charge, a
copy of our Annual Report on Form 10-K. Requests should be
mailed to W. Page Barnes, Corporate Secretary, 3326 Aspen Grove
Drive, Suite 150, Franklin, Tennessee 37067. You may also
access our Annual Report on Form 10-K on the investor
relations webpage of our Internet website, http://investors.chct.reit.
By Order of the Board
of Directors,

Timothy Wallace
Chairman of the Board
March 20, 2020
45
Table of
Contents
APPENDIX A—RECONCILIATION OF NON-GAAP FINANCIAL
MEASURES
Funds from
operations, ("FFO"), as defined by NAREIT, and adjusted funds from
operations ("AFFO"), are important non-GAAP supplemental measures
of operating performance for a REIT. Because the historical cost
accounting convention used for real estate assets requires
straight-line depreciation except on land, such accounting
presentation implies that the value of real estate assets
diminishes predictably over time. However, since real estate values
have historically risen or fallen with market and other conditions,
presentations of operating results for a REIT that uses historical
cost accounting for depreciation could be less informative. Thus,
NAREIT created FFO as a supplemental measure of operating
performance for REITs that excludes historical cost depreciation
and amortization, among other items, from net income, as defined by
GAAP.
NAREIT defines
FFO as the most commonly accepted and reported measure of a REIT's
operating performance equal to net income (computed in accordance
with GAAP), excluding gains (or losses) from sales of property and
impairments of real estate, plus depreciation and amortization
related to real estate properties, and after adjustments for
unconsolidated partnerships and joint ventures. NAREIT also
provides REITs with an option to exclude gains, losses and
impairments of assets that are incidental to the main business of
the REIT from the calculation of FFO.
The Company's
AFFO is defined as FFO, excluding non-cash income and expenses,
such as amortization of stock-based compensation, the effects of
straight-line rent, and others. The Company considers AFFO to be a
useful supplemental measure to evaluate the Company's operating
results excluding these income and expense items to help investors,
analysts and other interested parties compare the operating
performance of the Company between periods or as compared to other
companies on a more consistent basis.
Management
believes that net income, as defined by GAAP, is the most
appropriate earnings measurement. However, management believes FFO
and FFO per share to be supplemental measures of a REIT's
performance because they provide an understanding of the operating
performance of the Company's properties without giving effect to
certain significant non-cash items, primarily depreciation and
amortization expense. Historical cost accounting for real estate
assets in accordance with GAAP assumes that the value of real
estate assets diminishes predictably over time. However, real
estate values instead have historically risen or fallen with market
conditions.
The Company
believes that by excluding the effect of depreciation,
amortization, gains or losses from sales of real estate, impairment
of real estate, and gains, losses and impairment of incidental
assets, straight-line rent and amortization of stock-based
compensation, all of which are based on historical costs and which
may be of limited relevance in evaluating current performance, FFO
and AFFO can facilitate comparisons of operating performance
between periods. The Company reports FFO and AFFO per share because
these measures are observed by management to be some of the
predominant measures used by the REIT industry and by industry
analysts to evaluate REITs and because FFO per share, as defined by
NAREIT, is consistently reported, discussed, and compared by
research analysts in their notes and publications about REITs. For
these reasons, management has deemed it appropriate to disclose and
discuss FFO and AFFO per share. However, neither FFO or AFFO
represents cash generated from operating activities determined in
accordance with GAAP and are not necessarily indicative of cash
available to fund cash needs. FFO and AFFO should not be considered
alternatives to net income attributable to common stockholders or
as indicators of the Company's operating performance or as
alternatives to cash flow from operating activities as measures of
liquidity. The table below reconciles net income to FFO and
AFFO.
46
Table of
Contents
COMMUNITY HEALTHCARE TRUST INCORPORATED
RECONCILIATION OF FFO and AFFO
(Unaudited; Amounts in thousands, except per share
amounts)
|
|
|
|
|
|
|
|
|
|
Year Ended
December 31, |
|
|
|
2019 |
|
2018 |
|
Net income
|
|
$ |
8,376 |
|
$ |
4,403 |
|
Real estate depreciation and amortization
|
|
|
22,377 |
|
|
19,661 |
|
Impairment of note receivable(1)
|
|
|
— |
|
|
5,000 |
|
Income tax expense (benefit)(1)
|
|
|
1,321 |
|
|
(1,321 |
) |
Gain from sale of depreciable real estate
|
|
|
— |
|
|
(295 |
) |
|
|
|
|
|
|
|
|
Total adjustments
|
|
|
23,698 |
|
|
23,045 |
|
|
|
|
|
|
|
|
|
Funds from Operations (FFO)
|
|
$ |
32,074 |
|
$ |
27,448 |
|
Transaction costs
|
|
|
— |
|
|
57 |
|
Straight-line rent
|
|
|
(2,052 |
) |
|
(1,292 |
) |
Stock-based compensation
|
|
|
3,844 |
|
|
2,853 |
|
|
|
|
|
|
|
|
|
Adjusted Funds from Operations (AFFO)
|
|
$ |
33,866 |
|
$ |
29,066 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
FFO per Common Share-Diluted
|
|
$ |
1.67 |
|
$ |
1.53 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFO Per Common Share-Diluted
|
|
$ |
1.77 |
|
$ |
1.62 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average Common Shares
Outstanding-Diluted(2)
|
|
|
19,164 |
|
|
17,943 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- (1)
- In the fourth quarter
of 2018, the Company recorded a $5.0 million impairment
related to its mezzanine loan with Highland Hospital and recorded a
related tax benefit and deferred tax asset of approximately
$1.3 million. This deferred tax asset was impaired in the
fourth quarter of 2019 and the tax benefit was reversed resulting
in tax expense of $1.3 million. The Company believes that the
mezzanine loan is incidental to the main operations of the Company.
As such, the Company has excluded the impairment of the note
receivable and the related tax impact from its calculation of FFO.
The $5.0 million impairment on the loan and related tax
benefit of $1.3 million recorded in 2018 was previously
recognized as an adjustment to AFFO rather than FFO for the year
ended December 31, 2018 and has been reclassified as an
adjustment to Funds from Operations rather than to Adjusted Funds
from Operations for 2018 to conform to the current year
presentation.
- (2)
- Diluted weighted
average common shares outstanding for FFO are calculated based on
the treasury method, rather than the 2-class method used to
calculate earnings per share.
47
aNNuaL meeTiNg of sTocKhoLDeRs of
commuNiTy heaLThcaRe TRusT may 7, 2020 iNcoRpoRaTeD iNTeRNeT -
Access “www.voteproxy.com” and follow the on-screen instructions or
scan the QR code with your smartphone. Have your proxy card
available when you access the web page. Vote online until 11:59
PMESTthe day before the meeting. maiL - Sign, date and mail your
proxy card in the envelope provided as soon as possible. iNpeRsoN -
You may vote your shares in person by attending the Annual Meeting.
go gReeN - e-Consent makes it easy to go paperless. With e-Consent,
you can quickly access your proxy material, statements and other
eligible documents online, while reducing costs, clutter and paper
waste. Enroll today via www.astfinancial.com to enjoy online
access. Please detach along perforated line and mail in the
envelope provided IF you are not voting via the Internet.
20530040300000000000 0 050720 Incorporated approve, on a
non-binding advisory basis, the compensation Regulation S-K in the
Company’s proxy statement for the 2020 annual 1 YEAR 2 YEARS 3
YEARS ABSTAIN non-binding advisory vote on executive compensation.
Note: Please sign exactly as your name or names appear on this
Proxy. When shares are held jointly, each holder should sign. When
signing as executor, administrator, attorney, trustee or guardian,
please give full title as such. If the signer is a corporation,
please sign full corporate name by duly authorized officer, giving
full title as such. If signer is a partnership, please sign in
partnership name by authorized person. The boaRD of DiRecToRs
RecommeNDs a VoTe "foR" The eLecTioN of aLL of The NomiNees foR
DiRecToR, "foR" pRoposaL 2 aND 4, aND foR eVeRy “1 yeaR” oN
pRoposaL 3. pLease sigN, DaTe aND ReTuRN pRompTLy iN The eNcLoseD
eNVeLope. pLease maRK youR VoTe iN bLue oR bLacK iNK as showN heRe
x 1. To elect five (5) directors to the Board of Directors of the
Company, each to serve a one-year term expiring in 2021. NomiNees:
FOR ALL NOMINEESO Alan Gardner O Claire Gulmi WITHHOLD AUTHORITYO
Robert Hensley FOR ALL NOMINEESO Lawrence Van Horn O Timothy
Wallace FOR ALL EXCEPT (See instructions below) INSTRUCTIONS: To
withhold authority to vote for any individual nominee(s), mark “FOR
ALL EXCEPT” and fill in the circle next to each nominee you wish to
withhold, as shown here: FOR AGAINST ABSTAIN 2. To approve, on a
non-binding advisory basis, the following resolution: ResoLVeD,
that the stockholders of Community Healthcare Trust of the named
executive officers as disclosed pursuant to Item 402 of meeting of
stockholders. 3. To approve, on a non-binding advisory basis, the
frequency of a FOR AGAINST ABSTAIN 4. To ratify the appointment of
BDO USA, LLP as the Company’s independent registered public
accountants for 2020. 5. To transact such other business as may
properly come before the annual meeting or any adjournments
thereof. This pRoxy wheN pRopeRLy execuTeD wiLL be VoTeD as
DiRecTeD heReiN by The uNDeRsigNeD sTocKhoLDeR. if No DiRecTioN is
maDe, This pRoxy wiLL be VoTeD “foR aLL NomiNees” iN pRoposaL 1,
"foR" pRoposaL 2 aND 4, aND foR eVeRy “1 yeaR” oN pRoposaL 3. To
change the address on your account, please check the box at right
and indicate your new address in the address space above. Please
note that changes to the registered name(s) on the account may not
be submitted via this method. Signature of Stockholder Date:
Signature of StockholderDate: NoTice of iNTeRNeT aVaiLabiLiTy of
pRoxy maTeRiaL: The Notice of Meeting, proxy statement, proxy card
and annual report are available at http://investors.chct.reit/
compaNy NumbeR accouNT NumbeR pRoxy VoTiNg iNsTRucTioNs

- 0 COMMUNITY HEALTHCARE TRUST
INCORPORATED proxy for annual meeting of stockholders on may 7,
2020 solicited on behalf of the board of Directors The undersigned
hereby appoints Timothy G. Wallace and W. Page Barnes, and each of
them, with full power of substitution and power to act alone, as
proxies to vote all the shares of Common Stock which the
undersigned would be entitled to vote if personally present and
acting at the Annual Meeting of Stockholders of Community
Healthcare Trust Incorporated, to be held May 7, 2020 at 8:00 a.m.
Central Time at 3326 Aspen Grove Drive, Suite 150, Franklin,
Tennessee 37067, and at any adjournments or postponements thereof,
as follows: (continued and to be signed on the reverse side.) 14475
1.1

Commmunity Healthcare (NYSE:CHCT)
Historical Stock Chart
From Dec 2020 to Jan 2021
Commmunity Healthcare (NYSE:CHCT)
Historical Stock Chart
From Jan 2020 to Jan 2021